Fact-checked by Grok 2 weeks ago

Obstructive sleep apnea

Obstructive sleep apnea (OSA) is a common sleep disorder characterized by recurrent episodes of partial or complete upper airway obstruction during sleep, resulting in pauses in breathing (apnea) or reduced airflow (hypopnea) that last at least 10 seconds and occur multiple times per hour.^[1] This blockage leads to intermittent drops in blood oxygen levels, frequent awakenings, and disrupted sleep architecture, often manifesting as loud snoring, gasping for air, or choking sensations during the night.^[2] OSA is distinct from central sleep apnea, where the issue stems from the brain's failure to signal breathing muscles, and it represents the most prevalent form of sleep-disordered breathing.^[3] Prevalence is substantial and increasing due to rising obesity rates, estimated to affect more than 50 million adults in the United States (as of 2024), with global rates for moderate to severe cases (apnea-hypopnea index [AHI] ≥15 events/hour) ranging from approximately 10% to 17% in middle-aged adults, though varying widely by population and diagnostic criteria.^[4] ^[5] Risk factors include obesity (body mass index >30 kg/m²), male sex, age over 40 years, family history, anatomical features such as a narrow airway or large tonsils, smoking, and conditions like hypothyroidism or menopause.^[6] Symptoms include nocturnal disturbances like snoring and gasping, as well as excessive daytime sleepiness, morning headaches, dry mouth or sore throat upon waking, irritability, difficulty concentrating, and reduced libido.^[2] These often go unrecognized, contributing to underdiagnosis and high public health impact. The pathophysiology involves collapse of the pharyngeal airway during sleep due to reduced muscle tone, exacerbated by fat deposition around the upper airway or craniofacial abnormalities.^[7] Untreated OSA heightens risks of cardiovascular complications, including hypertension (present in up to 50% of resistant cases), coronary artery disease, stroke, and heart failure, as well as metabolic issues like type 2 diabetes and insulin resistance.^[8] Other complications include motor vehicle accidents from sleepiness, depression, and cognitive impairment.^[2] Diagnosis relies on polysomnography to measure the AHI, with mild OSA defined as 5-14 events per hour, moderate as 15-30, and severe as >30.^[1] Treatment is multifaceted: continuous positive airway pressure (CPAP) maintains airway patency and is first-line for moderate to severe cases, while lifestyle changes such as weight loss can reduce severity by 26% for every 10% reduction in body weight.^[9] Options also include oral appliances, positional therapy, and surgery like uvulopalatopharyngoplasty for select patients; pharmacotherapies targeting airway muscles are under investigation.^[1] Effective management improves quality of life, reduces cardiovascular risks, and prevents complications.^[10]

Classification

Severity assessment

The severity of obstructive sleep apnea (OSA) is clinically graded using the apnea-hypopnea index (AHI), a key metric derived from overnight sleep studies. The AHI is calculated by dividing the total number of apneas (complete cessation of airflow for ≥10 seconds) and hypopneas (partial airflow reduction with ≥3% oxygen desaturation or arousal) by the total hours of sleep.^[1] The American Academy of Sleep Medicine (AASM) defines OSA severity based on AHI thresholds as follows: mild (5–15 events per hour), moderate (15–30 events per hour), and severe (>30 events per hour).^[11] These criteria guide treatment decisions, with escalating intensity recommended for higher severity levels to mitigate associated health impacts. In 2023, the AASM updated its Manual for the Scoring of Sleep and Associated Events (version 3), shifting hypopnea scoring from an optional ≥4% desaturation criterion to the recommended ≥3% desaturation or arousal threshold, enhancing the sensitivity of AHI measurements without altering the severity classifications.^[12] Each severity level carries distinct clinical implications, with progressive correlation to symptom intensity and health risks. Mild OSA often presents with subtle sleep disruptions and lower-grade associations to fatigue and early cardiovascular strain, typically warranting conservative management like lifestyle modifications. Moderate OSA intensifies these effects, linking to greater sleep fragmentation and elevated intermediate risks such as hypertension, prompting consideration of therapies like positive airway pressure. Severe OSA markedly escalates symptom burden and long-term risks, including substantial increases in cardiovascular events, stroke, and overall mortality, necessitating aggressive interventions to prevent complications.^[1] Polysomnography serves as the gold standard for AHI determination.^[13]

Distinction from other apneas

Obstructive sleep apnea (OSA) differs fundamentally from central sleep apnea (CSA) and mixed sleep apnea in its etiology and physiological presentation, with OSA characterized by recurrent episodes of partial or complete upper airway obstruction during sleep despite persistent respiratory effort. In OSA, the collapse or blockage of the pharyngeal airway occurs due to anatomical factors and muscle relaxation, leading to airflow cessation while thoracoabdominal movements continue as the body attempts to breathe.^[1] Central sleep apnea, by contrast, arises from a failure of the central nervous system to generate appropriate respiratory drive, resulting in pauses in breathing without any thoracoabdominal effort; this lack of ventilatory drive distinguishes CSA from OSA, where effort is present but ineffective.^[14] Mixed sleep apnea combines elements of both, typically beginning with a central component (absent effort) that transitions into an obstructive phase (effort emerges against a blocked airway), often observed in patients with overlapping risk factors.^[15] OSA is the most prevalent form of sleep apnea, while CSA and mixed forms are far less prevalent, with CSA affecting only about 0.9% of adults over 40 in community-based cohorts.^[16] Key diagnostic features to differentiate these include monitoring thoracoabdominal movements—absent in pure CSA but present in OSA—and nasal pressure signals, which show airflow absence with effort in OSA versus no effort in CSA; mixed events display a sequential pattern in these signals.^[17] The apnea-hypopnea index (AHI), a measure of event frequency, applies across apnea types for severity assessment but requires consideration of the underlying mechanism for accurate classification.^[14]

Signs and symptoms

In adults

Obstructive sleep apnea (OSA) in adults presents with distinct nighttime and daytime manifestations, often reported by the patient or observed by a bed partner. These signs and symptoms arise from recurrent upper airway obstructions during sleep. Nighttime symptoms include loud snoring, which is often disruptive and habitual; episodes of paused breathing (apneas) lasting 10 seconds or more, frequently witnessed by others; abrupt awakenings accompanied by gasping, choking, or snorting sounds; and restless sleep with frequent position changes. Other common features are awakenings to urinate (nocturia), dry mouth or sore throat upon waking, and a sensation of choking.^[2]^[1] Daytime symptoms are primarily related to sleep fragmentation and include excessive sleepiness or drowsiness, which may lead to unintended dozing during activities like driving or working; morning headaches; difficulty concentrating or paying attention; irritability or mood changes such as depression; fatigue despite adequate sleep opportunity; and decreased libido. These symptoms can significantly impair daily functioning and quality of life.^[2]^[1]

In children

Obstructive sleep apnea (OSA) in children differs from adult presentations, often linked to adenotonsillar hypertrophy, and manifests through observable sleep disturbances and behavioral changes affecting growth and development. Nighttime symptoms include habitual snoring, which may be loud and accompanied by pauses in breathing; snorting, gasping, coughing, or choking sounds; restless sleep with frequent movements or unusual positions; mouth breathing; nighttime sweating; and bed-wetting (nocturnal enuresis), particularly if it begins after a period of being dry. Chest retractions or paradoxical breathing may also be observed.^[18]^[19] Daytime symptoms encompass excessive sleepiness, such as falling asleep in school or during short rides; morning headaches; trouble breathing through the nose leading to mouth breathing; behavioral issues resembling attention-deficit/hyperactivity disorder, including hyperactivity, inattention, impulsivity, or aggression; poor school performance or learning difficulties; and poor weight gain or growth delays. These can impact academic and social development.^[18]^[20]

Diagnosis

Clinical assessment

The clinical assessment of obstructive sleep apnea (OSA) involves a structured evaluation through patient history, physical examination, and validated screening tools to identify individuals at risk and guide subsequent testing. This initial process helps clinicians recognize symptoms and anatomical predispositions without relying on overnight monitoring.^[13] Patient history focuses on key symptoms, including habitual loud snoring, witnessed breathing pauses during sleep, unrefreshing sleep, and excessive daytime somnolence, often reported by the patient or bed partner. Questionnaires targeting these features are routinely employed to quantify risk. The Epworth Sleepiness Scale (ESS), a self-administered tool with eight scenarios rated from 0 to 3, measures average daytime sleepiness; scores exceeding 10 signal high risk for OSA-related morbidity and warrant further evaluation.^[21] Physical examination emphasizes upper airway anatomy and body habitus to detect features contributing to collapse during sleep. The Mallampati score, determined by visualizing the oropharynx with the mouth open and tongue protruded, grades airway patency from I (full visibility) to IV (minimal structures visible); scores of III or IV independently predict the presence and severity of OSA by indicating a crowded pharynx. Neck circumference measurement provides additional insight, with values greater than 17 inches (43 cm) in men and 16 inches (40 cm) in women associated with increased OSA risk due to adipose tissue impinging on the airway.^[22]^[23]^[24] Screening tools integrate history and exam findings for efficient risk stratification. The STOP-BANG questionnaire, comprising eight yes/no items on snoring, tiredness, observed apneas, high blood pressure, BMI over 35 kg/m², age over 50, neck circumference exceeding 40 cm, and male gender, is widely recommended; scores of 3 or higher identify moderate-to-severe OSA with high sensitivity, prompting referral for confirmatory testing. These elements collectively triage patients, with high-risk individuals prioritized for polysomnography to establish definitive diagnosis.^[25]^[13]

Polysomnography

Polysomnography (PSG), also known as a sleep study, serves as the reference standard for diagnosing obstructive sleep apnea (OSA) by providing a comprehensive evaluation of sleep-related breathing disturbances in a controlled laboratory setting.^[26] This overnight test records multiple physiological signals to assess sleep architecture, respiratory events, and associated arousals, enabling accurate identification of OSA severity and differentiation from other sleep disorders.^[27] The PSG procedure involves attaching sensors to the patient in a sleep laboratory, typically starting in the evening and continuing through the night until morning awakening. Key monitored parameters include electroencephalography (EEG) to determine sleep stages, electrooculography (EOG) for eye movements, electromyography (EMG) for chin and leg muscle activity, airflow measured via nasal pressure transducers or thermocouples, respiratory effort detected by thoracic and abdominal belts, and peripheral oxygen saturation via pulse oximetry.^[28] Additional recordings may encompass electrocardiography (ECG) for heart rate and video monitoring for behavior, all synchronized to capture interactions between sleep and respiratory function.^[29] A trained technician oversees the setup and monitoring to ensure signal quality, with the patient encouraged to sleep as naturally as possible in a private room.^[30] Interpretation of PSG data follows standardized scoring rules established by the American Academy of Sleep Medicine (AASM). An obstructive apnea is scored when there is a ≥90% reduction in airflow from baseline for ≥10 seconds in the presence of continued or increased inspiratory effort, distinguishing it from central apneas lacking effort.^[11] Hypopneas are defined as a ≥30% reduction in airflow for ≥10 seconds accompanied by either a ≥3% oxygen desaturation from pre-event baseline or an associated arousal, per the AASM's 2017 updates in the Manual for the Scoring of Sleep and Associated Events (version 2.4), which aimed to improve consistency and clinical relevance in adult OSA evaluations.^[31] These events are tallied to derive the apnea-hypopnea index (AHI), calculated as the number of apneas and hypopneas per hour of total sleep time.^[32] PSG offers significant advantages, including detailed insights into sleep stages, frequent arousals, and potential comorbidities like periodic limb movements, which enhance diagnostic precision beyond respiratory metrics alone.^[30] However, its limitations include high costs due to facility and staffing requirements, as well as the potential for disrupted sleep in an unfamiliar laboratory environment, which may underestimate OSA severity in some patients.^[30]

Home sleep apnea testing

Home sleep apnea testing (HSAT) involves the use of portable monitoring devices to diagnose obstructive sleep apnea (OSA) in non-laboratory settings, offering a convenient alternative to in-lab polysomnography for select patients. These devices are classified by the American Academy of Sleep Medicine (AASM) into Type III and Type IV categories based on the number of physiological channels recorded. Type III monitors typically include at least four channels, such as airflow, respiratory effort, oxygen saturation, and heart rate, while Type IV devices record fewer channels, often limited to airflow and oximetry.^[33]^[34] Examples of commercially available HSAT devices include the WatchPAT, a wrist-worn monitor that measures peripheral arterial tone (PAT) along with oximetry, actigraphy, and heart rate to estimate apnea-hypopnea index (AHI), and the ApneaLink, a portable unit that records nasal airflow, respiratory effort, and pulse oximetry. Home oximetry represents a subset of Type IV testing focused primarily on oxygen desaturation events, while PAT-based methods like those in WatchPAT provide additional vascular response data to infer respiratory events without direct airflow measurement. These devices are designed for simplicity, allowing patients to self-apply sensors before bedtime.^[35]^[36]^[37] The procedure for HSAT is self-administered and conducted overnight in the patient's home, typically involving the attachment of sensors to measure key respiratory and cardiovascular parameters for 6-8 hours. It is recommended by the AASM for uncomplicated adults with a moderate to high pretest probability of OSA based on clinical suspicion, such as snoring, daytime sleepiness, or witnessed apneas, but excluding those with significant comorbidities like heart failure, chronic obstructive pulmonary disease, or neuromuscular disorders. If the initial HSAT is negative, inconclusive, or technically inadequate, in-laboratory polysomnography is advised to confirm or rule out OSA.^[13]^[38] Validation studies demonstrate that AASM-approved HSAT devices provide reliable AHI estimation for diagnosing OSA, with overall accuracy around 80-90% compared to polysomnography in uncomplicated cases, particularly for detecting moderate to severe OSA (AHI ≥15 events/hour). For instance, the ApneaLink shows sensitivity and specificity of 91% and 95%, respectively, at this threshold, while WatchPAT achieves sensitivity of 81-95% and specificity of 66-100%. However, HSAT may underestimate OSA severity in rapid eye movement (REM) sleep or patients with comorbidities due to reliance on recording time rather than actual sleep time and inability to detect arousals or non-apneic events.^[13]^[37]^[39]^[40]

Diagnostic criteria

The diagnosis of obstructive sleep apnea (OSA) in adults is established according to criteria outlined in the International Classification of Sleep Disorders, Third Edition (ICSD-3), published by the American Academy of Sleep Medicine (AASM). These criteria require the presence of either (1) an apnea-hypopnea index (AHI) of 5 or more predominantly obstructive respiratory events per hour of sleep accompanied by one or more symptoms such as excessive daytime sleepiness, nonrestorative sleep, fatigue, insomnia, snoring, witnessed apneas, gasping or choking during sleep, or documented hypertension; or (2) an AHI of 15 or more predominantly obstructive events per hour without accompanying symptoms.^[41] The AHI is typically measured via polysomnography (PSG) or home sleep apnea testing (HST).^[42] To confirm OSA, respiratory events must be predominantly obstructive, meaning more than 50% of apneas and hypopneas are obstructive or mixed rather than central; if central events predominate, a diagnosis of central sleep apnea is considered instead.^[41] In patients with heart failure or recent stroke, evaluation for OSA is recommended at lower AHI thresholds due to heightened cardiovascular risks, even if standard symptomatic criteria are not fully met, to facilitate earlier intervention.^[43] For children, the AASM criteria differ, diagnosing OSA with an AHI of 1 or more obstructive events per hour of sleep, often accompanied by symptoms like snoring, labored breathing, or behavioral issues; severity is classified as mild (AHI 1-4.9), moderate (5-9.9), or severe (≥10).^[44] The 2023 update to the AASM Manual for the Scoring of Sleep and Associated Events (Version 3) refined respiratory event scoring rules, including explicit definitions for the oxygen desaturation index (ODI)—the number of oxygen desaturations of ≥3% or ≥4% per hour of sleep—which serves as a proxy for AHI in HST devices lacking effort sensors and supports diagnosis in resource-limited settings.^[45]

Pathophysiology

Mechanisms of obstruction

Obstructive sleep apnea (OSA) primarily involves the collapse of the pharyngeal airway during sleep, a segment of the upper airway that lacks rigid bony support and relies on surrounding soft tissues and muscles for patency. The pharynx extends from the nasopharynx to the larynx and is particularly susceptible to narrowing due to its flexible walls, which can be compressed by adjacent structures such as the tongue, soft palate, and lateral pharyngeal walls. During wakefulness, active muscle tone maintains airway stability, but sleep induces a reduction in neural drive to these dilator muscles, leading to hypotonia and increased collapsibility. This physiological change is exacerbated in OSA patients, where the critical closing pressure (Pcrit) of the pharynx— the pressure at which the airway collapses—shifts to more positive values, promoting partial or complete obstruction.^[46] Neural control of the upper airway plays a central role in this collapsibility, with the genioglossus muscle, the primary tongue protruder and pharyngeal dilator, being particularly critical. Innervated by the hypoglossal nerve, the genioglossus receives inputs from respiratory centers, chemoreceptors, and mechanoreceptors, generating phasic activity that peaks during inspiration to counteract collapsing forces. In OSA, however, there is a disproportionate reduction in genioglossus electromyographic (EMG) activity at sleep onset, failing to adequately dilate the airway and allowing posterior displacement of the tongue base. This dilation failure is more pronounced during non-rapid eye movement (NREM) sleep, where tonic and phasic muscle activations diminish, resulting in recurrent airway narrowing.^[47] A key biomechanical factor amplifying obstruction is the generation of negative intraluminal pressure within the pharynx, governed by the Bernoulli principle. As inspiratory airflow accelerates through a narrowed segment—due to initial partial collapse or anatomical narrowing—the principle dictates that fluid velocity inversely relates to pressure, creating subatmospheric intraluminal pressure that draws the flexible pharyngeal walls inward. This suction effect, combined with transmural pressure gradients favoring collapse, intensifies narrowing and can precipitate full occlusion, particularly when muscle tone is low. Diaphragmatic contraction further contributes to this negative pressure, pulling air through the restricted path and promoting a vicious cycle of worsening collapsibility.^[48] The resulting obstruction initiates a repetitive pathophysiological cycle in OSA. Airflow cessation leads to progressive hypoxia (reduced arterial oxygen) and hypercapnia (elevated carbon dioxide), which stimulate chemoreceptors and increase respiratory drive, escalating upper airway resistance against the collapsed segment. This heightened effort eventually triggers an arousal from sleep—typically after 10 to 60 seconds—restoring muscle tone and briefly reopening the airway. However, the arousal fragments sleep and resets the cycle, with events recurring hundreds of times per night, perpetuating intermittent obstruction without addressing underlying collapsibility. The intermittent hypoxia and reoxygenation also induce systemic inflammation, activating pathways such as hypoxia-inducible factor-1α (HIF-1α), nuclear factor kappa B (NF-κB) signaling, and the NLRP3 inflammasome, which promote chronic low-grade inflammation contributing to OSA's broader health impacts.^[49]^[50]

Contributing models

Obstructive sleep apnea (OSA) exhibits significant variability among individuals, which can be explained through phenotypic models that identify distinct pathophysiological traits contributing to airway instability during sleep. These models, developed from physiological studies, emphasize four primary endotypes: pharyngeal collapsibility, loop gain reflecting ventilatory control instability, arousal threshold, and compensatory upper airway muscle mechanics. Pharyngeal collapsibility refers to the propensity of the upper airway to narrow or collapse under negative pressure, quantified by critical closing pressure (Pcrit), where higher values indicate greater vulnerability to obstruction. Loop gain measures the sensitivity of the respiratory control system to disturbances, with elevated levels promoting overshoots in ventilation that destabilize breathing patterns. The arousal threshold represents the ventilatory drive required to trigger cortical arousal from sleep, often low in OSA patients, leading to frequent awakenings that perpetuate the cycle of apneas. Compensatory mechanics involve the responsiveness of dilator muscles, such as the genioglossus, to counteract collapsibility; impaired responsiveness exacerbates obstruction despite anatomical predisposition.^[51] These phenotypic traits enable personalized understanding of OSA progression, as combinations of elevated collapsibility, high loop gain, low arousal threshold, and poor muscle compensation account for disease severity in a substantial portion of patients. For instance, studies using polysomnography have shown that these traits are identifiable from spontaneous breathing variations during sleep, allowing non-invasive phenotyping to predict treatment outcomes. Therapy implications arise directly from targeting specific traits: patients with high loop gain benefit from supplemental oxygen, which stabilizes ventilatory control by mitigating hypocapnia-induced instability, reducing apnea-hypopnea index by up to 50% in responsive subgroups. Conversely, individuals with a low arousal threshold may respond to hypnotics like trazodone, which raise the threshold without excessively relaxing pharyngeal muscles, thereby decreasing arousal frequency and improving sleep continuity. Such phenotype-directed approaches, including combinations of oxygen and hypnotics, have demonstrated superior efficacy over standard continuous positive airway pressure in select cases, highlighting the model's clinical utility.^[52]^[53]^[54] Evolutionary models further contextualize OSA variability by positing that human airway adaptations, shaped by bipedalism and dietary shifts, predispose the pharynx to collapse, particularly in supine positions where gravitational forces exacerbate collapsibility compared to upright postures. These models suggest that the retropositioning of the tongue and narrowing of the oropharynx, evolutionary trade-offs for efficient upright breathing and vocalization, become maladaptive during supine sleep, increasing obstruction risk in modern humans who spend extended periods recumbent. Recent integrations in 2024 models incorporate respiratory control instability, such as dynamic loop gain assessments, into comprehensive frameworks that combine phenotyping with machine learning to forecast OSA progression and tailor interventions, emphasizing ventilatory instability's role alongside anatomical factors for precision medicine.^[55]^[56]

Risk factors

Obesity

Obesity is a primary risk factor for obstructive sleep apnea (OSA), primarily through mechanical effects that compromise upper airway patency during sleep. Excess adipose tissue deposition in the pharyngeal region narrows the airway lumen by increasing soft tissue collapsibility, particularly around the lateral pharyngeal walls and tongue base, which reduces the space available for airflow.^[57] Additionally, abdominal obesity contributes by elevating intra-abdominal pressure, which displaces the diaphragm cranially and increases respiratory effort, further predisposing the pharynx to collapse under negative intraluminal pressure.^[58] These mechanical loads interact with neural control mechanisms to heighten airway instability, exacerbating apneic events.^[59] Epidemiological data underscore the strong association between obesity and OSA risk. Individuals with a body mass index (BMI) greater than 30 kg/m² face approximately a 6-fold increased odds of developing OSA compared to those with normal weight.^[8] Furthermore, about 70% of patients diagnosed with OSA are obese, highlighting the condition's prevalence in this population.^[60] These risks can vary by ethnicity; for instance, Asian populations exhibit a higher susceptibility to OSA at lower BMI thresholds than Caucasians, often due to differences in craniofacial structure and fat distribution patterns that amplify mechanical effects even at moderate obesity levels.^[61] Weight loss offers a reversible pathway to mitigate OSA severity linked to obesity. A 10% reduction in body weight is associated with a 26% decrease in the apnea-hypopnea index (AHI), reflecting improved airway patency and reduced collapsibility.^[62] This dose-response relationship demonstrates obesity's causal role, as sustained weight reduction proportionally alleviates the mechanical burdens on the upper airway.^[63]

Anatomical and genetic factors

Obstructive sleep apnea (OSA) is frequently associated with specific craniofacial abnormalities that compromise upper airway patency. Conditions such as retrognathia and micrognathia, characterized by posterior positioning or underdevelopment of the mandible, reduce the pharyngeal airspace and increase collapsibility during sleep.^[64] Similarly, a high-arched palate contributes to a narrower nasopharyngeal pathway, exacerbating airflow resistance.^[65] These structural features are particularly evident in syndromic conditions; for instance, individuals with Down syndrome (trisomy 21) exhibit a prevalence of OSA ranging from 50% to 75%, attributed to midface hypoplasia, macroglossia, and ligamentous laxity.^[66] Airway-related anatomical traits further predispose individuals to OSA by promoting dynamic obstruction. A narrow oropharynx, often assessed via Mallampati scoring, limits the lateral dimensions of the pharynx, facilitating tissue collapse under negative intraluminal pressure.^[67] Enlarged soft tissues, including an oversized tongue or soft palate, encroach on the airway lumen, with magnetic resonance imaging studies confirming reduced cross-sectional areas in affected patients.^[68] These inherent traits can be temporarily worsened by obesity through additional fat deposition, amplifying collapsibility.^[69] Hypothyroidism increases OSA risk through mechanisms such as upper airway edema, macroglossia, and reduced muscle tone; studies indicate 10-25% of hypothyroid patients develop OSA, and thyroid hormone replacement can alleviate symptoms.^[70] Genetic factors play a significant role in OSA susceptibility, with evidence of familial aggregation indicating heritability. Individuals with a first-degree relative affected by OSA face a 2- to 4-fold increased risk, as demonstrated in population-based studies.^[71] Specific genetic variants, such as polymorphisms in the APOE gene (particularly the ε4 allele), have been linked to higher OSA risk, potentially through influences on lipid metabolism and inflammation.^[72] Similarly, variants in the TNF-α gene, including the -308G>A polymorphism, correlate with elevated tumor necrosis factor-alpha levels and OSA severity, promoting airway inflammation and edema.^[73] Certain ear, nose, and throat (ENT) surgeries can temporarily elevate OSA risk postoperatively due to edema, pain, or altered anatomy. Procedures like laser-assisted uvulopalatoplasty often result in a transient doubling of the respiratory disturbance index in the immediate recovery period, peaking around postoperative night 3 before resolving.^[74]^[75]

Age and sex

Obstructive sleep apnea (OSA) prevalence increases significantly with advancing age, particularly after the age of 40, due to age-related physiological changes such as loss of pharyngeal muscle tone and, in women, declining estrogen levels that exacerbate airway collapsibility.^[76] In individuals aged 65 years and older, the prevalence of moderate to severe OSA approaches 40%, reflecting a 2- to 3-fold higher rate compared to middle-aged adults (30-64 years).^[77] These changes contribute to greater upper airway instability during sleep, compounded briefly by any pre-existing anatomical narrowing.^[78] Sex differences play a prominent role in OSA susceptibility, with men exhibiting a 2- to 3-fold higher prevalence than women before menopause, largely attributable to hormonal influences including testosterone, which promotes central fat deposition around the upper airway and abdomen.^[78] Post-menopause, however, the prevalence equalizes between sexes as women's risk rises substantially.^[79] Hormonal shifts during menopause, marked by estrogen and progesterone decline, independently increase OSA risk by approximately 3-fold in women, further elevating vulnerability through altered fat distribution and reduced protective effects on airway muscle tone.^[80] Recent projections underscore the amplifying impact of an aging population on OSA burden; in 2024, an estimated 83.7 million U.S. adults aged 20 and older were living with OSA,^[5] with models forecasting a rise to 76.6 million adults aged 30-69 by 2050 due to demographic shifts toward older age groups.^[81] This trend highlights the need for heightened awareness and screening in aging cohorts to mitigate escalating public health implications.^[82]

Lifestyle and medications

Lifestyle factors play a significant role in exacerbating the risk of obstructive sleep apnea (OSA) by influencing upper airway stability and muscle tone. Alcohol consumption, even in moderate amounts, acts as a central nervous system depressant that relaxes the pharyngeal muscles, leading to increased airway collapsibility during sleep. Research indicates that regular alcohol intake is associated with a heightened OSA risk, with meta-analyses showing an approximate 25% increase overall, and heavier consumption (more than two drinks per episode) linked to more pronounced effects on apnea-hypopnea index (AHI) severity.^[83]^[84] Similarly, sedative use beyond alcohol, such as certain over-the-counter sleep aids, promotes similar muscle relaxation and has been tied to worsened OSA symptoms in susceptible individuals.^[85] Smoking is another key lifestyle contributor, as it induces chronic inflammation and edema in the upper airway mucosa, narrowing the passageway and elevating OSA risk. Longitudinal studies have demonstrated that current smokers face roughly twice the odds of developing OSA compared to non-smokers, with the inflammatory effects persisting even after cessation and compounding with pack-year exposure.^[86]^[87] Sleep position further modulates severity; the supine posture increases gravitational pull on the tongue and soft palate, often amplifying AHI by 2 to 4 times relative to lateral sleeping, particularly in positional OSA cases where non-supine events are minimal.^[88]^[89] Certain medications heighten OSA vulnerability by impairing respiratory control and airway patency. Opioids, commonly prescribed for pain management, suppress central respiratory drive and diminish arousal responses to apneas, with chronic use strongly associated with the emergence of central and obstructive sleep-disordered breathing patterns.^[90]^[91] Benzodiazepines, used for anxiety or insomnia, similarly reduce upper airway muscle tone and prolong apnea duration, increasing hypoxia risk in those with underlying OSA; concomitant use with opioids amplifies these effects, leading to higher odds of severe events.^[92]^[93] Muscle relaxants, including agents like baclofen, exacerbate pharyngeal instability by directly weakening dilator muscles, thereby promoting airway collapse and elevating AHI in affected patients.^[94]^[95] Nasal congestion arising from allergens, such as in allergic rhinitis, contributes to OSA risk by increasing nasal resistance and shifting breathing to the mouth, which destabilizes the upper airway. Epidemiological data reveal that individuals with allergy-related nasal obstruction are about 1.8 times more likely to experience moderate-to-severe sleep-disordered breathing, with inflammation further promoting collapsibility during sleep.^[96]^[97] These lifestyle and pharmacological factors often interact synergistically with obesity, amplifying overall airway obstruction vulnerability.^[98]

Environmental influences

Environmental factors play a significant role in exacerbating the risk and severity of obstructive sleep apnea (OSA) by influencing physiological processes such as airway patency and sleep quality. Rising global temperatures associated with climate change have been shown to worsen OSA symptoms through mechanisms including dehydration and systemic inflammation, which can increase upper airway collapsibility. A 2025 study presented at the American Thoracic Society International Conference found that higher temperatures (27.3°C vs. 6.4°C) are associated with a 70% increased odds of experiencing OSA on a given night, highlighting the potential for climate warming to substantially elevate the global burden of OSA.^[99] High-altitude environments, typically above 1,500 meters, pose additional risks for individuals with OSA due to hypobaric hypoxia, which promotes central apneas and intensifies overall breathing disturbances during sleep. At altitudes exceeding 1,600 meters, the reduced oxygen availability exacerbates hypoxemia in untreated OSA patients, leading to more frequent arousals and fragmented sleep. This hypoxic stress can transform predominantly obstructive events into mixed or central apneas, further complicating diagnosis and management in highland populations or travelers.^[100] Exposure to poor air quality, particularly fine particulate matter (PM2.5 and PM10), is linked to increased OSA severity via oxidative stress and airway inflammation, which narrow the upper airway and heighten obstruction propensity. Pollutants induce epithelial damage and edema in the respiratory tract, promoting chronic low-grade inflammation that disrupts normal ventilatory control during sleep. Studies have demonstrated that higher ambient levels of nitrogen dioxide (NO2) and particulate matter correlate with elevated AHI scores, underscoring air pollution as a modifiable environmental contributor to OSA progression.^[101] Occupational exposures, such as shift work, disrupt circadian rhythms and sleep architecture, thereby amplifying OSA risk by increasing the frequency of respiratory events and oxygen desaturations. Night shifts alter slow-wave and REM sleep stages, leading to heightened upper airway instability and a greater oxygen desaturation index (ODI) in affected workers. Research indicates that shift workers with OSA experience more severe daytime symptoms and impaired recovery compared to non-shift counterparts, emphasizing the need for targeted screening in high-risk professions.^[102]

Consequences

In children

Obstructive sleep apnea (OSA) in children exerts profound effects on development, distinct from those in adults due to the vulnerability of growing organ systems. Untreated pediatric OSA disrupts sleep architecture, leading to intermittent hypoxia and fragmented sleep that impair multiple physiological processes. This results in neurocognitive, behavioral, somatic, metabolic, and cardiovascular consequences, with potential persistence into adulthood if not addressed. Systemic inflammation further exacerbates these issues, contributing to a cycle of morbidity. Recent studies as of 2024 confirm that persistent OSA heightens long-term risks for adult cardiometabolic disease.^[103] Children with OSA often exhibit neurocognitive and behavioral deficits resembling attention-deficit/hyperactivity disorder (ADHD), including hyperactivity, inattention, and impulsivity.^[20] These symptoms arise from chronic sleep disruption and hypoxia, which affect brain regions involved in executive function and attention. Learning deficits are common, manifesting as poor academic performance and difficulties with memory and problem-solving. Studies indicate that untreated OSA can reduce full-scale IQ by approximately 5-10 points compared to peers without the condition, highlighting the impact on intellectual development.^[104] Somatic and metabolic effects include growth stunting, primarily due to suppression of growth hormone (GH) secretion during disrupted slow-wave sleep stages.^[105] This leads to delayed linear growth and failure to thrive, with recovery observed post-treatment in many cases. Untreated OSA also heightens obesity risk through metabolic dysregulation, including insulin resistance and altered energy balance, independent of initial body weight. Cardiovascular strain is evident, with children experiencing elevated blood pressure and hypertension risk nearly three times higher than unaffected peers, particularly if OSA persists into adolescence.^[106] Additional complications encompass nocturnal enuresis, occurring at an increased rate in children with OSA compared to controls, with odds nearly twice as high.^[19] Systemic inflammation, marked by elevated C-reactive protein and inflammatory cytokines, is a constitutive feature even in non-obese children, promoting endothelial dysfunction and amplifying organ-specific harms.^[107] Long-term, untreated pediatric OSA increases the likelihood of persistence into adulthood, with only about 30% achieving remission by early adulthood, perpetuating risks for chronic neurobehavioral impairments and cardiometabolic disease.^[108] This underscores the need for early intervention to mitigate lifelong sequelae.

In adults

Obstructive sleep apnea (OSA) in adults is associated with a range of multisystem complications, primarily stemming from chronic intermittent hypoxia, sleep fragmentation, and sympathetic activation. These effects manifest across neurocognitive, cardiovascular, metabolic, psychological, and other domains, contributing to significant morbidity and reduced functional capacity. Untreated OSA exacerbates these issues, highlighting the importance of early recognition in adult populations. Neurocognitive complications include impairments in memory, attention, and executive function, which are commonly observed in adults with OSA due to disrupted sleep architecture and hypoxemia. Studies have demonstrated that multiple domains of cognition, such as verbal and visual memory, are affected in OSA patients. Furthermore, OSA is linked to an increased risk of dementia, with evidence suggesting approximately a twofold higher incidence compared to individuals without the disorder. This association is particularly noted with Alzheimer's disease and vascular dementia pathways. Additionally, the excessive daytime sleepiness and cognitive deficits associated with OSA elevate the risk of motor vehicle accidents by 2 to 7 times, as shown in meta-analyses of crash rates among untreated patients. Cardiovascular and metabolic complications are among the most prevalent in adults with OSA. Hypertension affects up to 50% of OSA cases, driven by nocturnal surges in blood pressure and endothelial dysfunction. The odds ratio for heart failure in OSA patients is approximately 2.3, reflecting heightened strain on cardiac function from repeated apneic episodes. Metabolic disturbances include an elevated risk of type 2 diabetes, with an odds ratio of about 1.6 independent of obesity, attributed to insulin resistance induced by hypoxia and inflammation. Stroke risk is similarly amplified, increasing 2 to 4 times in adults with moderate to severe OSA, as evidenced by cohort studies and meta-analyses linking OSA severity to cerebrovascular events. Psychological complications encompass a doubled prevalence of depression and anxiety disorders in adults with OSA, often bidirectional with sleep disruption exacerbating mood disturbances. This comorbidity contributes to a markedly reduced quality of life, with affected individuals reporting lower scores on standardized health-related quality of life measures due to persistent fatigue and emotional burden. Other complications include pulmonary hypertension, which occurs with increased frequency in OSA due to hypoxic vasoconstriction, and erectile dysfunction, prevalent in up to 70% of male OSA patients and linked to vascular and hormonal disruptions. These effects underscore the broad impact of OSA on adult health, distinct from pediatric manifestations focused on growth and development.

Management

Lifestyle modifications

Lifestyle modifications represent a foundational, non-invasive approach to managing obstructive sleep apnea (OSA), often serving as first-line or complementary strategies to alleviate symptoms and reduce apnea-hypopnea index (AHI) severity. These changes target modifiable risk factors like body weight, sleep positioning, substance use, and daily habits, with evidence supporting their role in improving airway patency and sleep quality. Weight management is particularly critical for individuals with obesity, a major contributor to upper airway collapse in OSA. A 10% reduction in body weight has been associated with a 26% decrease in AHI, demonstrating a clear dose-response relationship where greater weight loss correlates with more pronounced improvements in respiratory events and oxygenation. Structured diet and exercise programs, emphasizing caloric restriction and regular physical activity, facilitate this loss and are recommended by clinical guidelines for obese OSA patients. For instance, interventions combining aerobic exercise with dietary counseling can yield sustained AHI reductions of 25-30% with modest 10% weight loss, enhancing overall cardiovascular health as well.^[62]^[109] Positional therapy addresses the exacerbation of OSA in the supine position, affecting up to 50-60% of patients with position-dependent symptoms. By encouraging lateral or prone sleeping, this strategy reduces gravitational forces on the airway. The tennis ball technique—sewing a tennis ball into the back of sleepwear to prevent rolling onto the back—effectively minimizes supine time and achieves treatment success (AHI <10 events/hour) in about 61% of positional OSA cases. More advanced positional devices, such as vibrotactile feedback wearables, offer similar efficacy with better long-term adherence, reducing overall AHI by up to 50% in suitable patients without the discomfort of traditional methods.^[110]^[111] Avoiding alcohol, sedatives, and smoking is essential to prevent relaxation of pharyngeal muscles and inflammation that worsen airway obstruction. Alcohol consumption, even in moderation, increases AHI by 20-30% in the hours following intake by diminishing upper airway tone, so abstinence 4-6 hours before bedtime is advised. Sedatives like benzodiazepines similarly impair muscle responsiveness, heightening apneic risk, while smoking induces mucosal edema and narrows the airway; cessation can mitigate these effects within weeks, potentially lowering OSA severity by reducing inflammation.^[112]^[113]^[114] Sleep hygiene practices optimize the sleep environment and routine to support airway stability. Maintaining a consistent sleep schedule aligns circadian rhythms, reducing sleep fragmentation and indirectly lowering AHI through improved sleep efficiency. Nasal hygiene, including saline irrigation or sprays, clears congestion to promote nasal breathing, which maintains positive airway pressure and decreases oral breathing-related obstructions in 40-50% of cases with nasal involvement. Integrating these habits—such as avoiding heavy meals before bed and ensuring a cool, dark sleep space—enhances the efficacy of other modifications.^[115]^[9]

Positive airway pressure therapy

Positive airway pressure (PAP) therapy serves as a cornerstone treatment for obstructive sleep apnea (OSA) in adults, delivering pressurized air through a mask to maintain airway patency during sleep. The most common form, continuous positive airway pressure (CPAP), provides a constant stream of air at a fixed pressure level, typically ranging from 5 to 20 cm H₂O, to stent open the upper airway and prevent collapse.^[116] This therapy is recommended as the initial treatment for moderate to severe OSA by clinical guidelines, with evidence showing it effectively eliminates apneic events in the majority of patients when used appropriately.^[117] Variants of CPAP include auto-adjusting positive airway pressure (APAP), which dynamically varies pressure based on real-time airflow detection to match breathing needs, and bilevel positive airway pressure (BPAP), which delivers higher pressure during inhalation and lower during exhalation. APAP is often used for patients with variable obstruction or those intolerant to fixed pressures, demonstrating equivalent efficacy to CPAP in normalizing the apnea-hypopnea index (AHI) and improving daytime sleepiness.^[118] BPAP is particularly indicated for complex cases, such as OSA with hypoventilation or central apnea components, where it enhances comfort and ventilation support compared to CPAP.^[119] Efficacy data indicate that PAP therapy reduces AHI by more than 90% in compliant patients, leading to substantial improvements in sleep quality, excessive daytime somnolence, and quality of life. In hypertensive individuals with OSA, consistent CPAP use lowers systolic blood pressure by 2 to 4 mmHg on average, with greater reductions observed in those with severe disease or poor baseline control.^[120] These benefits are most pronounced with nightly use exceeding 4 hours, underscoring the importance of adherence.^[121] Despite its effectiveness, PAP therapy faces challenges with patient adherence, reported at 50-60% for regular use (defined as ≥4 hours per night on ≥70% of nights), primarily due to side effects such as mask discomfort, nasal congestion, dry mouth, and claustrophobia. Common adverse effects include interface-related issues like skin irritation and pressure-induced aerophagia, which can be mitigated with humidification, mask fitting adjustments, or alternative interfaces. Recent advancements, including mobile apps for usage tracking and telemonitoring, have improved adherence rates to around 75% at 90 days in some cohorts by enabling remote coaching and personalized feedback.^[122]^[123]

Oral appliances

Oral appliances are non-invasive devices worn in the mouth during sleep to treat obstructive sleep apnea (OSA) by maintaining an open airway, primarily through repositioning the lower jaw or tongue. These devices are particularly suited for patients with mild to moderate OSA or those who cannot tolerate continuous positive airway pressure (CPAP) therapy. The two main types include mandibular advancement devices (MADs), also known as mandibular advancement splints (MAS), which protrude the lower jaw forward by 5-10 mm to enlarge the pharyngeal airway, and tongue-retaining devices (TRDs), which use suction to hold the tongue in a forward position to prevent it from collapsing backward.^[124]^[125] Efficacy of oral appliances varies by type and OSA severity, with MADs demonstrating a mean apnea-hypopnea index (AHI) reduction of approximately 50% in mild to moderate cases, achieving treatment success (defined as ≥50% AHI reduction and post-treatment AHI <10 events/hour) in 60-70% of patients. TRDs are similarly effective for moderate to severe OSA, though less commonly used due to comfort issues, and both types perform best in positional OSA where apneas occur primarily in the supine position. Oral appliances can serve as an adjunct to positional therapy to enhance outcomes in such cases. Custom-fabricated devices, fitted by qualified dental professionals, outperform over-the-counter "boil-and-bite" options, which provide inconsistent advancement and lower AHI reductions (up to 23% less effective in mild OSA).^[126]^[127]^[128] According to the American Academy of Sleep Medicine (AASM) clinical practice guideline, sleep physicians should prescribe custom oral appliances rather than no therapy for adult patients with OSA who request alternatives to CPAP or are intolerant to it, particularly for mild to moderate severity, and for primary snoring without OSA. Indications include CPAP non-adherence, patient preference for a portable option, and cases with contraindications to surgery. Common side effects are generally mild and transient, including jaw pain, tooth or gum discomfort, temporomandibular joint issues, excessive salivation, and dry mouth, with rare long-term dental changes like bite alterations if not monitored. Patients require follow-up with titration and polysomnography to assess efficacy and manage side effects.^[129]^[130]

Surgical interventions

Surgical interventions for obstructive sleep apnea (OSA) aim to address anatomical obstructions in the upper airway by altering tissue structure or function, offering potential long-term solutions for patients intolerant to conservative therapies. These procedures range from soft tissue resections to skeletal advancements and neuromodulation implants, with efficacy varying by patient anatomy, severity of OSA, and procedure type. Success is typically measured by a reduction in the apnea-hypopnea index (AHI) to below 20 events per hour alongside a 50% decrease from baseline, though outcomes depend on careful patient selection.^[131] Uvulopalatopharyngoplasty (UPPP) involves the surgical removal of excess tissue from the soft palate, uvula, and pharyngeal walls to widen the airway. This procedure, often performed under general anesthesia, targets retropalatal collapse but has shown variable long-term success rates of 40-50% in reducing AHI significantly. A meta-analysis of long-term outcomes indicated a 46.1% average decrease in AHI events per hour postoperatively, though satisfaction diminishes over time with nearly 50% of patients dissatisfied after 20 years. Complications may include velopharyngeal insufficiency leading to nasal regurgitation, but UPPP remains a common initial surgical option for selected adults with mild to moderate OSA.^[132]^[133] Hypoglossal nerve stimulation (HGNS) utilizes an implanted device to electrically stimulate the hypoglossal nerve during sleep, promoting forward tongue protrusion to prevent airway collapse. Approved by the FDA in 2025 for moderate to severe OSA (AHI 15-65), systems like the Genio provide leadless, externally rechargeable options for patients with central apnea-hypopnea index below 10. Clinical trials reported a 68% median reduction in AHI at 12 months in moderate-severe cases, with a 65% responder rate achieving at least 50% improvement. Adherence is high at over 80%, and the procedure involves outpatient implantation with risks including tongue weakness or infection, making it suitable for CPAP non-adherents.^[134]^[135] Maxillomandibular advancement (MMA) surgically repositions the maxilla and mandible forward to enlarge the pharyngeal airway, primarily for patients with severe anatomical deficiencies such as retrognathia. This orthognathic procedure yields high success rates of approximately 85%, with meta-analyses confirming sustained AHI reductions maintained over 5 years in most cases. Among 427 patients in a recent review, 88.1% met surgical success criteria, though transient skeletal complications like numbness occur in up to 50% of cases. MMA is reserved for severe, refractory OSA due to its invasiveness but offers cure rates around 40% for eliminating symptoms entirely.^[136]^[137] In children, tonsillectomy with or without adenoidectomy is the primary surgical intervention for OSA caused by lymphoid hypertrophy, often curing the condition in 75-100% of otherwise healthy, non-obese cases. Success rates reach 80% in non-obese children, with polysomnography showing normalized AHI postoperatively in most under age 7. Risks include postoperative bleeding in 2-5% and rare velopharyngeal insufficiency affecting speech or swallowing in less than 1%. This procedure is typically outpatient and first-line before considering advanced options in pediatric populations.^[138]^[139]^[140]

Pharmacological treatments

Pharmacological treatments for obstructive sleep apnea (OSA) primarily address symptoms such as excessive daytime sleepiness (EDS) or underlying contributors like obesity and upper airway muscle instability, rather than providing a cure. These therapies are often used as adjuncts to primary interventions like positive airway pressure, with limited options directly targeting the core pathophysiology of airway collapse during sleep.^[141]^[142] Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, was approved by the FDA in 2018 for treating EDS associated with OSA in adults. Clinical trials have demonstrated its efficacy in increasing wakefulness and reducing sleepiness, with significant improvements in maintenance of wakefulness test scores compared to placebo, without directly impacting apnea-hypopnea index (AHI). It is typically dosed at 75-150 mg daily and is well-tolerated, though common side effects include headache, nausea, and decreased appetite. Despite its benefits for EDS, solriamfetol does not alter the underlying OSA severity and is not a standalone treatment.^[143]^[144]^[145] In December 2024, the FDA approved tirzepatide, a dual GLP-1 and GIP receptor agonist, as the first medication specifically for moderate to severe OSA in adults with obesity, to be used alongside dietary changes and exercise. Administered as a weekly subcutaneous injection (starting at 2.5 mg, titrated up to 15 mg), tirzepatide promotes substantial weight loss, which indirectly reduces OSA severity; phase 3 SURMOUNT-OSA trials showed a least-squares mean AHI reduction of 27.5 events per hour versus placebo after one year, with 62% of treated patients achieving mild or no OSA compared to 21% on placebo. This improvement is mediated by reductions in body weight (up to 20%) and hypoxic burden, enhancing oxygenation during sleep. However, gastrointestinal side effects such as nausea, diarrhea, vomiting, and constipation are common, particularly during dose escalation, and it is contraindicated in patients with a history of medullary thyroid carcinoma.^[146]^[141]^[147] Emerging therapies aim to directly enhance upper airway muscle tone. AD109, an investigational oral combination of atomoxetine (a norepinephrine reuptake inhibitor) and aroxybutynin (an antimuscarinic agent), targets neuromuscular instability by increasing noradrenergic stimulation to dilator muscles, thereby preventing collapse without relying on weight loss. Phase 3 trials, including SynAIRgy and LunAIRo completed in 2025, reported significant AHI reductions (up to 50% in moderate to severe OSA) and improvements in oxygenation over 6-12 months compared to placebo, across a range of body weights and OSA severities. As of late 2025, AD109 remains in late-stage development awaiting regulatory approval, with a favorable safety profile but potential side effects including dry mouth and constipation.^[148]^[149]^[150] Adjunct pharmacological options include nasal corticosteroids, such as fluticasone, which alleviate nasal congestion and rhinitis-related obstruction in select OSA patients. Intranasal steroids have shown modest AHI reductions (e.g., from 11 to 6 events per hour in children with mild OSA) and improved continuous positive airway pressure (CPAP) adherence by reducing symptoms like rhinorrhea, though they are not effective as monotherapy for most adults. Theophylline, a phosphodiesterase inhibitor that enhances respiratory muscle tone, has demonstrated limited benefits in reducing AHI (e.g., 51% in heart failure patients with OSA) but is rarely used due to narrow therapeutic index, cardiac risks, and sleep disruption.^[151]^[152]^[153]^[154]^[155] Overall, pharmacological approaches for OSA fill critical gaps in symptom management and adjunctive care but lack a universal cure, with efficacy varying by patient factors like obesity and adherence. Ongoing research emphasizes combination strategies, yet side effects and the absence of direct airway-stabilizing drugs for non-obese patients highlight persistent limitations.^[156]^[157]^[158]

Prognosis

Treatment outcomes

Continuous positive airway pressure (CPAP) therapy effectively controls obstructive sleep apnea (OSA) severity in 70-80% of patients by significantly reducing the apnea-hypopnea index (AHI), with meta-analyses showing AHI reductions of 76-83% across ethnic groups.^[137] However, long-term adherence remains a challenge, with 30-50% of patients becoming nonadherent over time, defined as less than 4 hours of nightly use on at least 70% of nights.^[159] This nonadherence limits the overall benefits, as adherent patients experience sustained improvements in sleep quality and daytime function. Surgical interventions for OSA, such as hypoglossal nerve stimulation (HGNS), demonstrate variable outcomes, with approximately 60% of patients classified as responders in pivotal trials like the STAR study, achieving at least a 50% AHI reduction and post-treatment AHI below 20 events per hour.^[160] Oral appliances achieve success in about 50% of cases, typically defined as reducing AHI to below 10 events per hour, though rates range from 30-85% depending on device design and OSA severity.^[161] Overall, effective OSA treatment reduces mortality risks compared to untreated cases, with CPAP users showing a 20-30% lower cardiovascular disease (CVD) risk and up to 37% reduction in all-cause mortality in meta-analyses of observational studies.^[162] Patient education strategies, including detailed explanations of OSA pathophysiology and device use, improve adherence by approximately 20%, as evidenced by higher compliance rates in educated cohorts.^[163] Lifestyle factors, such as weight management, can enhance these outcomes when combined with primary therapies.

Long-term risks

Untreated obstructive sleep apnea (OSA) significantly elevates the risk of cardiovascular disease (CVD), with studies indicating a 2- to 3-fold increase in conditions such as heart failure, stroke, and coronary heart disease. For instance, the Sleep Heart Health Study reported an odds ratio of 2.38 for prevalent heart failure among individuals with OSA compared to controls, independent of other risk factors. Similarly, meta-analyses have shown a 60% increased risk of stroke (odds ratio 1.6) and up to 140% for heart failure. Regarding mortality, untreated OSA is linked to higher all-cause mortality, with adjusted odds ratios ranging from 1.5 to 2.0; in elderly populations, hazard ratios for cardiovascular mortality reach 2.25. These risks stem from chronic intermittent hypoxia and sympathetic activation, which promote atherosclerosis and endothelial dysfunction over time.^[164]^[165]^[166] Disease progression in untreated OSA is notable, with approximately 6% of adults with no or mild disease progressing to moderate or severe forms over 4 years, as observed in the Wisconsin Sleep Cohort Study, even without significant weight gain.^[167] This progression exacerbates hypoxemia and fragmentation of sleep, amplifying downstream health impacts. Economically, the burden of untreated OSA in the United States is approximately $203 billion annually as of 2025, encompassing direct healthcare expenditures, productivity losses, and motor vehicle accidents.^[168] Effective treatment, such as continuous positive airway pressure (CPAP), can substantially mitigate these long-term risks, halving the incidence of cardiovascular events within 1 to 3 years in adherent patients. Clinical trials have demonstrated up to a 64% reduction in composite cardiovascular outcomes with consistent therapy, underscoring the reversibility of OSA-related harm when addressed promptly.^[169]^[170] Recent 2025 research further reveals that climate change amplifies OSA severity through rising ambient temperatures, which correlate with increased apnea-hypopnea indices and reduced sleep efficiency, potentially accelerating disease progression and global burden by up to double under warming scenarios.^[171]

Epidemiology

Global prevalence

Obstructive sleep apnea (OSA) affects an estimated 936 million adults aged 30-69 years worldwide with mild to severe disease (apnea-hypopnea index [AHI] ≥5 events per hour), representing a substantial global health burden.^[172] Of these, approximately 425 million individuals have moderate to severe OSA (AHI ≥15 events per hour), for which effective treatments are available but often underutilized.^[172] In the general adult population, the prevalence of moderate to severe OSA is approximately 13% among men and 6% among women, with higher rates observed in middle-aged groups.^[173] Prevalence varies regionally, with notably higher rates in Asia despite lower average body mass index (BMI) levels compared to Western populations; Asians experience increased OSA risk at BMI thresholds as low as 25 kg/m², contributing to elevated occurrence in countries like China and India.^[174] Underdiagnosis remains a critical issue globally, with 80-90% of cases undetected due to limited screening and awareness, particularly in low- and middle-income regions.^[175] The rising obesity epidemic has driven increasing OSA prevalence over recent decades, paralleling global weight gain trends and exacerbating the condition's incidence by 20-30% in affected populations.^[175] In children, OSA prevalence is estimated at 1-5% worldwide, often linked to adenotonsillar hypertrophy and peaking between ages 2-8 years, though underdiagnosis is similarly high at around 80%.^[176] These figures underscore the need for enhanced diagnostic efforts across age groups to mitigate associated cardiovascular and neurocognitive risks.^[176]

Demographic variations

Obstructive sleep apnea (OSA) demonstrates notable differences in prevalence across demographic categories, influenced by biological, hormonal, and social factors. In terms of sex, OSA is approximately twice as common in men as in women, with a typical male-to-female ratio of 2:1 in the general adult population.^[177] This disparity largely equalizes after menopause, as the prevalence in postmenopausal women rises to levels comparable to those in men of similar age, potentially due to hormonal changes.^[178] Women overall face lower diagnosis rates for OSA, often because their symptoms—such as fatigue, insomnia, and mood disturbances—differ from the classic snoring and witnessed apneas more commonly reported in men, leading to underrecognition by healthcare providers.^[179] Prevalence increases progressively with age, with the highest rates occurring in the 60-70 year age group, where community-based studies report figures ranging from 27% to 80% depending on diagnostic criteria.^[180] Among middle-aged adults aged 30-49 years, moderate-to-severe OSA affects about 10% of men and 3% of women, though mild forms contribute to overall rates approaching 20-26% in this demographic when including broader apnea-hypopnea index thresholds.^[181]^[174] Ethnic variations show elevated OSA prevalence among African Americans, with odds ratios of approximately 1.8 to 2.0 compared to non-Hispanic whites, alongside higher severity at younger ages.^[182] Hispanics also experience increased rates relative to whites, potentially linked to higher obesity prevalence in these groups.^[61] Socioeconomic status correlates with higher OSA prevalence in low-income populations, driven primarily by elevated obesity rates and limited access to diagnostic and preventive healthcare services.^[183] These barriers exacerbate underdiagnosis and untreated disease in affected communities.^[184]

Future projections

Projections indicate that obstructive sleep apnea (OSA) will impose a significantly greater burden on public health systems in the coming decades, driven primarily by demographic shifts, rising obesity rates, and environmental factors such as climate change. In the United States, modeling estimates that OSA will affect 76.6 million adults aged 30–69 years by 2050, marking a 35% relative increase from 2020 levels.^[185] This escalation reflects ongoing trends in population aging and obesity, with particularly sharp rises anticipated among women, where prevalence could increase by 65% to reach 30.4 million cases.^[185] Globally, the burden is expected to rise due to escalating obesity epidemics and climate-related changes that heighten respiratory vulnerabilities during sleep, with potential increases in prevalence linked to warming temperatures.^[171] The expanding prevalence of OSA is expected to exacerbate healthcare strains worldwide, including increased demands on diagnostic and treatment resources amid already high undiagnosed rates. In the US, the annual economic burden of OSA was estimated at over $150 billion as of recent studies.^[186] These costs highlight the condition's growing impact on workforce participation and cardiovascular health outcomes, with untreated cases contributing disproportionately to emergency care and chronic disease management.^[185] On a global scale, similar pressures are anticipated, as obesity prevalence continues to rise in low- and middle-income countries, compounding access barriers in resource-limited settings.^[171] Mitigating this trajectory will require proactive measures, such as enhanced screening programs to identify at-risk individuals earlier. Such strategies, integrated with public health efforts to address obesity and climate influences, offer a pathway to reduce the long-term healthcare demands and economic toll of OSA.^[171]

Society and culture

Public awareness

Public awareness of obstructive sleep apnea (OSA) remains limited, with an estimated 80% of cases undiagnosed in the United States, contributing to delayed treatment and heightened health risks.^[187] Organizations such as the American Academy of Sleep Medicine (AASM) have launched targeted campaigns to address this gap, including the "More than a Snore" initiative in 2023, which emphasizes that OSA extends beyond simple snoring to impact long-term health and quality of life.^[188] Similarly, the AASM's "Sleep is Good Medicine" campaign, introduced in 2022, promotes education on sleep's role in overall well-being, while annual events like World Sleep Day, supported by the AASM Foundation, feature interactive resources to engage families in recognizing sleep disorders.^[189]^[190] Societal stigma surrounding OSA often portrays snoring as a humorous or minor annoyance, which discourages individuals from seeking medical evaluation and perpetuates underdiagnosis.^[191] This perception is particularly pronounced among women, who may remain silent about symptoms due to embarrassment or gender biases that associate snoring primarily with men, leading to misattribution of fatigue and other signs to stress or hormonal issues rather than OSA.^[192] Such delays in diagnosis exacerbate risks, as women with OSA frequently present with subtler symptoms like insomnia or depression, further complicating recognition.^[193] Media coverage and celebrity disclosures have played a growing role in elevating awareness, with public figures like Shaquille O'Neal and Amy Poehler openly discussing their experiences with CPAP therapy for OSA, helping to normalize treatment.^[194] Post-2020, interest surged amid links between OSA and COVID-19 complications, prompting increased online searches and discussions about sleep health during the pandemic.^[195] In 2025, emerging public health alerts have highlighted connections between climate change and OSA, noting that rising temperatures worsen symptom severity and could double the global burden by 2100 without mitigation efforts.^[171]^[196] These developments underscore the need for broader education to combat stigma and promote early intervention.

Healthcare access and policies

Access to healthcare for obstructive sleep apnea (OSA) varies significantly across regions, influenced by clinical guidelines, insurance policies, and socioeconomic factors. In the United States, the American Academy of Sleep Medicine (AASM) provides key guidelines for OSA screening and diagnosis, with the 2017 clinical practice guideline for diagnostic testing—endorsed by the World Sleep Society in 2021—recommending polysomnography or home sleep apnea testing (HSAT) for adults with increased risk of moderate to severe OSA.^[42] Recent AASM updates, including 2023 quality measures for pediatric OSA care and a 2025 guideline for inpatient screening in high-risk hospitalized adults, emphasize integrated evaluation pathways to facilitate timely diagnosis and positive airway pressure (PAP) therapy initiation.^[197]^[198] In Europe, the 2023 European Insomnia Guideline incorporates OSA screening recommendations, advising home sleep apnea testing or polysomnography following positive questionnaire results to confirm diagnosis.^[199] Insurance coverage for CPAP and HSAT aligns with these guidelines; for instance, most U.S. health plans, including Medicare, cover HSAT when prescribed for suspected OSA, provided it meets criteria like a high pretest probability.^[200] Disparities in OSA diagnosis and treatment are pronounced in low-resource settings, particularly in Africa, where data scarcity and limited infrastructure result in very low diagnosis rates despite high prevalence of risk factors such as obesity and hypertension. Studies indicate that OSA-related symptoms are common among African adults, but access to diagnostic facilities like sleep labs remains severely restricted, leading to underdiagnosis and untreated cases that exacerbate cardiovascular risks.^[201]00046-7/abstract) The COVID-19 pandemic highlighted these gaps but also spurred telemedicine adoption, which has improved OSA management access; for example, telemedicine visits accounted for 47% of sleep medicine consultations in the post-acute phase, enabling remote PAP titration and follow-up to reduce barriers in underserved areas.^[202]^[203] Policy frameworks further shape OSA care accessibility. In the United States, Medicare covers PAP devices, including CPAP, for beneficiaries diagnosed with OSA via an approved sleep test, offering a 12-week rental trial period to assess efficacy, after which continued coverage requires documented adherence and clinical benefit.^[204] In the European Union, Directive 2006/126/EC, implemented across member states, mandates screening for obstructive sleep apnea in professional drivers to mitigate road safety risks, requiring referral for moderate or severe cases and treatment compliance for license renewal, with tools like the EUROSAS questionnaire validated for this purpose.^[205]^[206] Despite these advances, gaps persist, particularly in pediatric OSA, where barriers such as limited provider training, long wait times for polysomnography, and high loss-to-follow-up rates hinder timely diagnosis and intervention. Cost remains a significant obstacle, with CPAP devices and initial setups ranging from $500 to $1,100 out-of-pocket without insurance, though full annual supplies can exceed $1,000, disproportionately affecting low-income families and contributing to treatment nonadherence.^[207]^[208]^[209]

Research

Recent advancements

In recent years, significant progress has been made in device-based therapies for obstructive sleep apnea (OSA). The Inspire hypoglossal nerve stimulation (HGNS) system received FDA approval in June 2023 for expanded indications, allowing treatment for patients with apnea-hypopnea index (AHI) up to 100 events per hour and increasing the upper body mass index (BMI) limit from 32 to 40 kg/m², thereby broadening access for a larger patient population previously excluded due to higher BMI.^[210]^[211] This expansion was supported by clinical data demonstrating sustained efficacy in reducing AHI and improving quality of life in these extended cohorts.^[212] Pharmacological advancements have also emerged as novel options for OSA management. In December 2024, the FDA approved tirzepatide (Zepbound) as the first medication specifically for moderate to severe OSA in adults with obesity, based on phase 3 trials showing significant AHI reductions of up to 62% alongside substantial weight loss.^[146]^[213] Complementing this, AD109—a fixed-dose combination of aroxybutynin and atomoxetine—demonstrated success in its phase 3 LunAIRo trial reported in July 2025, achieving a mean AHI reduction of 46.8% at 26 weeks compared to 6.8% with placebo, with benefits persisting through 51 weeks across BMI categories.^[148]^[214] These developments mark a shift toward oral therapies targeting upper airway neuromuscular tone.^[215] Diagnostic innovations have improved the accessibility and precision of OSA evaluation. Studies in 2024 highlighted AI-enhanced home sleep testing (HST) achieving approximately 90% sensitivity and specificity in detecting moderate to severe OSA, leveraging machine learning algorithms on wearable biosignals like oximetry and actigraphy to match polysomnography accuracy while reducing costs and wait times.^[216]^[217] For instance, AI models analyzing mandibular jaw movements and oxygen desaturation patterns have enabled reliable at-home screening with over 90% agreement to in-lab results in validation cohorts.^[218] Emerging research has linked environmental factors to OSA pathophysiology. A study presented at the American Thoracic Society (ATS) 2025 International Conference established that rising global temperatures exacerbate OSA severity, with higher ambient temperatures linked to a 45% increased likelihood of OSA on a given night due to heightened respiratory instability and altered sleep architecture.^[99] This climate-OSA connection underscores the need for adaptive management strategies in warming regions.^[219]

Ongoing trials and directions

Current clinical trials for obstructive sleep apnea (OSA) are exploring novel pharmacological interventions beyond traditional positive airway pressure therapy. The phase 3 trials for AD109, a fixed-dose combination of aroxybutynin and atomoxetine targeting upper airway neuromuscular control via enhanced hypoglossal nerve activity through noradrenergic and cholinergic pathways, were completed in 2025, with topline results from the LunAIRo study demonstrating significant reductions in apnea-hypopnea index (AHI) across mild to severe OSA cases and a planned New Drug Application submission to the FDA in early 2026.^[148] Additional data presentations at the CHEST 2025 meeting highlight its potential for once-daily oral administration.^[220] Similarly, extension studies of tirzepatide, a dual GLP-1/GIP receptor agonist, are investigating its effects on OSA severity in obese patients, revealing weight-independent improvements in AHI and nocturnal hypoxia through mechanisms possibly involving respiratory control enhancement.^[221] Emerging research directions emphasize precision medicine approaches, such as phenotyping OSA endotypes to tailor therapies, with ongoing trials like NCT06825923 evaluating multidimensional models integrating physiological, genetic, and symptomatic data for personalized treatment predictions. Gene therapy remains a preclinical focus, aiming to restore pharyngeal muscle tone by targeting hypoglossal motor neurons, as demonstrated in murine models where viral vectors increased neurotransmitter expression to prevent airway collapse.^[222] In pediatric OSA, trials are assessing long-term outcomes of adenotonsillectomy, including residual disease persistence and neurocognitive effects, with recent randomized controlled trials showing sustained improvements in quality of life but highlighting the need for follow-up beyond five years in up to 40% of cases with incomplete resolution.^[223] Climate adaptation studies are also gaining traction, exploring how rising ambient temperatures exacerbate pediatric OSA severity through altered sleep architecture and increased collapsibility, informing adaptive strategies in vulnerable populations.^[171] Key challenges in OSA management include improving treatment adherence via wearable technologies, with ongoing research testing consumer devices for real-time CPAP monitoring and behavioral nudges to boost compliance rates above 70%.^[224] Additionally, biomarker development for early detection is prioritized, focusing on immunological and metabolic panels like C-reactive protein and erythropoietin to screen at-risk individuals before polysomnography, though validation in diverse cohorts remains essential.^[225]

References

[1]
Obstructive Sleep Apnea - StatPearls - NCBI Bookshelf
Mar 4, 2025 · Obstructive sleep apnea (OSA) is a sleep disorder characterized by repeated episodes of complete (apnea) or partial (hypopnea) collapse of the upper airway.
[2]
Obstructive sleep apnea - Symptoms and causes - Mayo Clinic
Jul 14, 2023 · Symptoms · Excessive daytime sleepiness. · Waking in the morning with a dry mouth or sore throat. · Morning headaches. · Trouble focusing. · Mood ...
[3]
What Is Sleep Apnea? - NHLBI - NIH
Jan 9, 2025 · Obstructive sleep apnea, also called OSA, happens when your upper airway becomes blocked many times while you sleep. The blockage can reduce or ...Causes and Risk Factors · Treatment · Sleep Apnea in Children · Symptoms
[4]
Rising prevalence of sleep apnea in U.S. threatens public health
Jul 29, 2024 · Public health and safety are threatened by the increasing prevalence of obstructive sleep apnea, which now afflicts at least 25 million adults in the US.
[5]
Sleep Apnea - Causes and Risk Factors - NHLBI
Jan 9, 2025 · Obstructive sleep apnea is caused by conditions that block airflow through your upper airway during sleep. For example, your tongue may fall ...
[6]
Adult Obstructive Sleep Apnea: Pathophysiology and Diagnosis - PMC
Obstructive sleep apnea (OSA) is a highly prevalent disease characterized by recurrent episodes of upper airway obstruction that result in recurrent arousals.
[7]
Association and Risk Factors for Obstructive Sleep Apnea and ...
Epidemiologic studies show that sleep apnea increases cardiovascular diseases risk factors including hypertension, obesity, and diabetes mellitus.
[8]
Obstructive sleep apnea - Diagnosis and treatment - Mayo Clinic
Jul 14, 2023 · Studies show that weight loss medications can help improve symptoms of obstructive sleep apnea. The U.S. Food and Drug Administration recently ...Symptoms and causes · Doctors and departments · Care at Mayo Clinic
[9]
Obstructive sleep apnea syndrome: natural history, diagnosis, and ...
Sleep apnea is an entity characterized by repetitive upper airway obstruction resulting in nocturnal hypoxia and sleep fragmentation.<|control11|><|separator|>
[10]
AASM Scoring Manual - American Academy of Sleep Medicine
Apr 9, 2025 · This comprehensive and evolving resource provides rules for scoring sleep stages, arousals, respiratory events during sleep, movements during sleep and cardiac ...
[11]
[PDF] The AASM Manual for the Scoring of Sleep and Associated Events
All AASM-accredited sleep facilities are required to implement the new rules in Version 3 by December 31, 2023. The following summary provides an overview of ...<|control11|><|separator|>
[12]
[PDF] Clinical Practice Guideline for Diagnostic Testing for Adult ...
Introduction: This guideline establishes clinical practice recommendations for the diagnosis of obstructive sleep apnea (OSA) in adults and is intended.
[13]
Central Sleep Apnea - StatPearls - NCBI Bookshelf
Diagnosis of treatment-emergent central apnea requires to have a primary diagnosis of OSA (with an apnea-hypopnea index ≥ 5 obstructive respiratory events per ...
[14]
Differentiating Obstructive from Central and Complex Sleep Apnea ...
Complex sleep apnea is different from central sleep apnea as the majority of apneas and hypopneas are obstructive, but the oscillatory pattern has a strong ...
[15]
Prevalence of obstructive sleep apnea in the general population
With this systematic review we aimed to determine the prevalence of obstructive sleep apnea (OSA) in adults in the general population and how it varied ...
[16]
Analyses from the Sleep Heart Health Study Cohort - PMC
According to contemporary criteria in the largest sleep cohort available, the current work demonstrates CSA prevalence to be 0.9% in adults aged 40 and older.
[17]
Distinguishing central from obstructive hypopneas on a clinical ...
In contrast to obstructive apnea, central apnea (Figure 2) is defined by the absence of both airflow and effort, revealed by the absence of thoracoabdominal ...Skip main navigation · INTRODUCTION · DISTINGUISHING... · SUMMARY
[18]
Obstructive Sleep Apnea in Children: Implications for the ...
Both habitual snoring and OSA are associated with behavioral problems, particularly hyperactivity and ADHD (1, 2, 11, 66). Hyperactive and inattentive behaviors ...
[19]
Childhood Obstructive Sleep Apnea Associates with ...
Aug 22, 2006 · They found that relative to controls, children with severe OSA had lower IQ and ability to perform tasks involving decision making. Children ...
[20]
Correction of obstructive sleep apnea and sleep en-gained growth ...
Since the bulk of growth hormone (GH) is secreted in relation to slow wave sleep (SWS), disordered sleep may hinder GH release and subsequent growth.Missing: suppression | Show results with:suppression
[21]
Study links sleep apnea in children to increased risk of high blood ...
Jun 23, 2021 · Children with obstructive sleep apnea are nearly three times more likely to develop high blood pressure when they become teenagers than children who never ...
[22]
Nocturnal enuresis is associated with moderate-to-severe ... - PubMed
Nocturnal enuresis is associated with moderate-to-severe obstructive sleep apnea in children with snoring ... odds ratio = 1.92 (1.08-3.43); P = 0.03). Presence ...
[23]
Systemic Inflammation in Non-Obese Children With Obstructive ...
Systemic inflammation is a constitutive component and consequence of OSA in many children, even in the absence of obesity, and is reversible upon treatment ...
[24]
Management of Persistent, Post-adenotonsillectomy Obstructive ...
Evidence suggests that OSA remission is seen in only 30% of children as they reach adulthood, thus contributing to the huge medical burden of OSA in adults (16) ...
[25]
The Epworth sleepiness scale in the identification of obstructive ...
The Epworth sleepiness scale (ESS) is often used clinically to screen for the manifestations of the behavioral morbidity associated to obstructive sleep apnea ...
[26]
Mallampati score as an independent predictor of obstructive sleep ...
Measurements and results: The Mallampati score was an independent predictor of both the presence and severity of obstructive sleep apnea.
[27]
Mallampati Score - StatPearls - NCBI Bookshelf - NIH
Jul 7, 2025 · The Mallampati score has been identified as an independent predictor of both the presence and severity of OSA. The odds of having OSA double for ...
[28]
Mayo Clinic Q and A: Neck size one risk factor for obstructive sleep ...
Jun 20, 2015 · A neck size greater than 16 or 17 inches is a sign of excess fat in the neck area. This may contribute to crowding and narrowing of your breathing tube.
[29]
Use and Performance of the STOP-Bang Questionnaire for ...
Mar 8, 2021 · The STOP-Bang questionnaire has adequate sensitivity and diagnostic accuracy for detecting moderate to severe obstructive sleep apnea across geographic regions.
[30]
Obstructive Sleep Apnea Diagnosis - Stanford Health Care
The gold standard for diagnosis is a Polysomnography (PSG), or, sleep study. This test is performed while the patient is asleep at a sleep laboratory.
[31]
Overview of Polysomnography, Parameters Monitored, Staging of ...
Nov 15, 2023 · PSG is non-invasive and consists of a simultaneous recording of multiple physiologic parameters related to sleep and wakefulness.
[32]
Sleep Study: What It Is, What To Expect, Types & Results
Sleep Study (Polysomnography). A sleep study is a diagnostic test that involves recording multiple systems in your body while you sleep.
[33]
Polysomnography Information | Mount Sinai - New York
Polysomnography is a sleep study. This test records certain body functions as you sleep, or try to sleep. Polysomnography is used to diagnose sleep disorders.How The Test Is Performed · Why The Test Is Performed · Normal Results
[34]
Testing - Division of Sleep Medicine - Harvard University
Advantages of polysomnography include the following: Technician is continuously present to adjust signals for optimal recording; Sleep is recorded; Other sleep ...
[35]
AASM clarifies hypopnea scoring criteria
Nov 7, 2017 · The AASM continues to recommend scoring hypopneas in adults when there is a ≥ 3% oxygen desaturation from pre-event baseline and/or the event is associated ...
[36]
Polysomnography in Patients With Obstructive Sleep Apnea
Polysomnography measures several sleep variables, one of which is the apnea-hypopnea index (AHI) or respiratory disturbance index (RDI). The AHI is defined as ...
[37]
Sleep Testing for Obstructive Sleep Apnea (OSA) (CAG-00405N)
Type III monitors have a minimum of 4 monitored channels including ventilation or airflow (at least two channels of respiratory movement or respiratory movement ...Decision · II. Background · III. History of Medicare Coverage
[38]
Accuracy of Type III Portable Monitors for Diagnosing Obstructive ...
PM devices are divided into three classes by the AASM criteria: type II, which has a minimum of seven channels; type III, which has a minimum of four channels; ...
[39]
FDA-cleared home sleep apnea testing devices | npj Digital Medicine
May 13, 2024 · ... devices, and the AASM recommends Type-3 devices for routine sleep testing. Type-4 devices may simplify testing; however, their clinical ...
[40]
Accuracy of WatchPAT for the Diagnosis of Obstructive Sleep Apnea ...
Jan 22, 2020 · The WatchPAT (Itamar Medical) is a home sleep apnea testing (HSAT) device which has been shown to be accurate for diagnosing sleep-disordered ...
[41]
Validation of the ApneaLink™ for the Screening of Sleep Apnea
The ApneaLink device had the highest sensitivity and specificity at an AHI value of 15 or more events per hour (91% and 95%, respectively). It also showed high ...
[42]
Clinical Use of a Home Sleep Apnea Test: An Updated American ...
Historically, HSAT devices have been classified (eg, Type III or Type IV) according to the number and type of sensors that are utilized. In contrast to ...<|control11|><|separator|>
[43]
The role of the WatchPAT device in the diagnosis and management ...
The WatchPAT device has reported sensitivities of 81–95%, specificities of 66–100%, positive predictive values of 79–96%, and negative predictive values of 92% ...
[44]
Underestimation of Sleep Apnea With Home Sleep Apnea Testing ...
It has been noted in previous studies that HSAT might underestimate overall severity of sleep apnea because of the measurement of TRT and not the TST.Missing: comorbidities REM
[45]
Polysomnography for Obstructive Sleep Apnea Should Include ...
During PSG, arousal-based respiratory scoring should be performed in the clinical evaluation of patients with suspected OSA.
[46]
Clinical Practice Guideline for Diagnostic Testing for Adult ...
This guideline establishes clinical practice recommendations for the diagnosis of obstructive sleep apnea (OSA) in adults.
[47]
Obstructive Sleep Apnea and Cardiovascular Disease
Jun 21, 2021 · OSA prevalence is as high as 40% to 80% in patients with hypertension, heart failure, coronary artery disease, pulmonary hypertension, atrial fibrillation, and ...Missing: odds ratio
[48]
American Academy of Sleep Medicine Position Paper for the Use of ...
Oct 15, 2017 · Diagnosis of OSA in children is based, in part, on the apneahypopnea index (AHI) identified by PSG that indicates whether there are an abnormal ...ABSTRACT · INTRODUCTION · BACKGROUND · POSITION STATEMENT
[49]
AASM releases updated version of scoring manual
Feb 15, 2023 · On Feb. 15, 2023, the American Academy of Sleep Medicine released the AASM Manual for the Scoring of Sleep and Associated Events, Version 3.
[50]
PHARYNGEAL MOTOR CONTROL AND THE PATHOGENESIS OF ...
As airway collapse in OSA occurs primarily in the pharyngeal airway and pharyngeal dilator muscles can influence both airway wall deformability and tissue ...
[51]
Obstructive Sleep Apnea: Emerging Treatments Targeting the ...
Oct 22, 2019 · The genioglossus (GG) is the main upper airway dilator muscle. Currently, continuous positive airway pressure is the first-line treatment for OSA.
[52]
Mechanisms and Management of Obstructive Sleep Apnea
According to Bernoulli's principle, airflow velocity increases as it passes through narrowed airway segments, resulting in reduced intraluminal air pressure and ...
[53]
Brain circuitry mediating arousal from obstructive sleep apnea - PMC
Jun 28, 2013 · The accumulating CO2 and hypoxia drive increasing respiratory effort in turn producing progressively greater and greater negative airway ...
[54]
Defining Phenotypic Causes of Obstructive Sleep Apnea ...
A total of 36% of patients with OSA had minimal genioglossus muscle responsiveness during sleep, 37% had a low arousal threshold, and 36% had high loop gain. A ...
[55]
Phenotyping Pharyngeal Pathophysiology using Polysomnography ...
Jul 14, 2017 · Our study shows that a patient's phenotypic mechanisms of OSA are apparent from the spontaneous changes in ventilation and ventilatory drive during sleep.
[56]
Identifying obstructive sleep apnoea patients responsive to ...
Here we test whether elevated loop gain and three key endophenotypic traits (collapsibility, compensation and arousability), quantified using clinical ...
[57]
Combination of Supplemental Oxygen and a Hypnotic Markedly ...
Our study demonstrates that the combination of drugs/agents targeting loop gain and the arousal threshold is a beneficial treatment option in patients whose ...
[58]
[PDF] Anatomy of Obstructive Sleep Apnea: An Evolutionary and ...
12 This adaptation led to retroposition of the tongue and narrowing of the airway, thereby facilitating upper airway obstruction by the tongue. Given the ...Missing: supine | Show results with:supine
[59]
The Present and Future of the Clinical Use of Physiological Traits for ...
Mar 13, 2024 · We discuss how anatomical and physiological factors that cause sleep apnea (OSA traits) impact treatment response and may offer an avenue for more precise care.2. Osa Traits · 2.2. 1. Ventilator Control... · 2.2. 3. Low Arousal...
[60]
Obesity and obstructive sleep apnoea: mechanisms for ... - PubMed
Obesity should structurally increase the collapsibility of the pharyngeal airway due to excessive fat deposition at two distinct locations.
[61]
Abdominal Fat and Sleep Apnea | Diabetes Care
Feb 1, 2008 · While it is well documented that obesity can result in OSA via several mechanisms, recent evidence suggests that OSA can worsen obesity.
[62]
Obesity: the major preventable risk factor of obstructive sleep apnea
It is proposed that increased peri-pharyngeal fat deposition results in mechanical loading that offsets the maintenance of airway patency by the dilator muscles ...
[63]
Obesity, Sleep Apnea, and Hypertension
Whereas obesity increases the risk for OSA, sleep apnea may predispose to weight gain and obesity. Indeed, patients with newly diagnosed OSA have a history ...Interactions Between Obesity... · Potential Contribution Of... · Obesity And Sympathetic...
[64]
Disparities and Genetic Risk Factors in Obstructive Sleep Apnea - NIH
Asians and Asian Americans appear to have comparable rates of OSA to whites despite markedly lower levels of obesity. OSA Risk Factors. Understanding the basis ...
[65]
Obstructive Sleep Apnoea Syndrome and Weight Loss: Review - PMC
... AHI while a 10% weight loss predicted a 26% (95% CI 18–34%) decrease in AHI. Further, a 10% increase in weight predicted a 6-fold (95% CI 2.2–17.0) increase ...
[66]
Obstructive Sleep Apnea and Cardiometabolic Disease: Obesity ...
Aug 14, 2025 · In particular, fat accumulation around the neck leads to a mechanical load on the pharyngeal structures, narrowing the upper airway. Moreover, ...
[67]
Correlation Between Severity of Obstructive Sleep Apnea and ... - NIH
Oct 11, 2025 · Key anatomical features associated with an increased risk of OSA include mandibular deficiencies, such as retrognathia or micrognathia, which ...
[68]
Polysomnographic Profile and Clinical Phenotypes of Osa in ...
Aug 13, 2025 · To the extrinsic factors belong fat deposits, hypertrophy of tissues, and craniofacial ... micrognathia/retrognathia, and a high-arched palate. A ...
[69]
Prevalence of Obstructive Sleep Apnea in Children with Down ... - NIH
Based upon full night polysomnography, an overall 66.4% prevalence of OSA was found in children with Down syndrome.
[70]
Translation of obstructive sleep apnea pathophysiology and ...
Aug 24, 2023 · The majority of patients with OSA have a narrowed oropharyngeal airway, a finding that can be clinically assessed by the Mallampati score (13).
[71]
Characteristics and Mechanism of Upper Airway Collapse Revealed ...
Nov 1, 2023 · 11,12 MRI studies have shown that OSA patients are characterized by an oversized tongue and soft palate, narrowed cross-sectional areas of the ...Missing: enlarged | Show results with:enlarged
[72]
Pathophysiology of Sleep Apnea - PMC - PubMed Central
Upper airway obstruction in sleep is most prevalent in the human in part because the hyoid bone, a key anchoring site for pharyngeal dilator muscles, is not ...
[73]
Familial predisposition and cosegregation analysis of adult ...
The risk ratio for a first-degree relative of a patient with OSAS was 2.0 (1.7-2.8, 95% confidence interval). The risk ratio of the more severely affected ...
[74]
APOE epsilon4 is associated with obstructive sleep apnea/hypopnea
Aug 24, 2004 · The APOE epsilon4 allele is associated with increased risk of OSAH, particularly in individuals under age 65. The mechanisms underlying this ...
[75]
Association between tumor necrosis factor alpha and obstructive ...
Aug 12, 2020 · Tumor necrosis factor-α (TNF-α) has been reported to play a part in the development of obstructive sleep apnea (OSA) and its complications.
[76]
implications for the outpatient treatment of obstructive sleep apnea ...
After LAUP, the mean RDI nearly doubled to 21.7 +/- 9.9 (P > .1). The apnea index increased fourfold from 3.3 +/- 3.5 to 14.8 +/- 10.9 (P < .03). The mean LSAT ...Missing: ENT | Show results with:ENT<|control11|><|separator|>
[77]
Surgical management of obstructive sleep apnoea: A position ... - NIH
Post‐operative disruption in sleep architecture is greatest across the first night, with a reduction in sleep efficiency, slow wave sleep and rapid eye movement ...
[78]
Obstructive Sleep Apnea and Aging: A Narrative Review
While OSA is widely known to be more common in men, it remains highly prevalent in elderly women. One study found that 50.9% of women (mean age, 68 years) in ...Epidemiology · Management In Older Patients · Osa And Cognitive Decline
[79]
[PDF] Risk Factors for Obstructive Sleep Apnea in Adults
Obstructive sleep apnea prevalence is high in patients with hypertension, and a causal role of OSA in hyperten- sion has been suggested by several stud- ies.<|control11|><|separator|>
[80]
Epidemiological aspects of obstructive sleep apnea - Garvey
OSA is present in 41% of patients with a body mass index (BMI) greater than 28 and the prevalence can be as high as 78% in patients referred for bariatric ...Introduction · Prevalence of OSA · OSA and obesity · Epidemiology of co-morbidity...
[81]
Gender, age and menopause effects on the prevalence and the ...
Aug 8, 2025 · Premenopausal women have a lower prevalence and milder severity of OSA than men; however, post-menopausal women have the same incidence rate as ...<|control11|><|separator|>
[82]
Obstructive Sleep Apnea and Menopause
Compared to premenopausal women, the odds for developing OSA increases two- to threefold for postmenopausal women. The increased risk remains even after ...<|control11|><|separator|>
[83]
Projecting the 30-year burden of obstructive sleep apnoea in the USA
Aug 26, 2025 · Projections indicate that obstructive sleep apnoea will affect 76·6 million adults aged 30–69 years across the USA in 2050, with a ...
[84]
Projecting the 30-year burden of obstructive sleep apnoea in the USA
Aug 26, 2025 · As life expectancy continues to increase, the proportion of older adults in the USA will rise,11 with middle and older age being a key risk ...Missing: elderly | Show results with:elderly
[85]
Alcohol and the risk of sleep apnoea: a systematic review and meta ...
Alcohol consumption increased the risk of sleep apnoea by 25%. · Findings were robust to differences in definitions of alcohol consumption and sleep apnoea.
[86]
Alcohol as an independent risk factor for obstructive sleep apnea
Jun 10, 2021 · In this study, we found that alcohol consumption was an independent risk factor of OSA and OSA with hypoxia, and alcohol consumption was related to AHI ...
[87]
The Impact of Alcohol on Breathing Parameters during Sleep
Alcohol, a muscle relaxant, can potentially worsen obstructive sleep apnea (OSA) but the literature on the effects of alcohol on OSA is conflicting.
[88]
Smoking and Obstructive Sleep Apnea: Is There An Association ...
Smoking induces upper airway chronic inflammation contributing to OSA symptoms [18,19]. Active, passive, as well as former smoking has been associated with ...
[89]
Association between smoking and obstructive sleep apnea based ...
Jun 5, 2023 · Smoking is widely known to negatively affect respiratory function, causing inflammation and swelling of the upper airway23.
[90]
Influence of Body Position on Severity of Obstructive Sleep Apnea
Supine sleep posture is consistently associated with more severe obstructive sleep apnea indices in adults, but this appears to be less consistent in pediatric ...
[91]
Supine position related obstructive sleep apnea in adults - PubMed
May 10, 2013 · The most striking feature of obstructive respiratory events is that they are at their most severe and frequent in the supine sleeping position ...
[92]
Opioid Therapy and Sleep Disorders: Risks and Mitigation Strategies
There was credible evidence of a strong relationship between opioids and sleep disordered breathing with noted risk factors including use of methadone, high ...
[93]
Chronic Opioid Use is a Risk Factor for the Development of Central ...
Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing. J Clin Sleep Med 2007;3(5):455-461. Keywords: Opioids, ...
[94]
Association of Opioid and Benzodiazepine Use with Adverse ...
Given the adverse impact of opioids and benzodiazepines on upper airway muscle tone, central chemosensitivity, and arousability (31–35), patients with overlap ...
[95]
Concomitant benzodiazepine and opioids decrease sleep apnoea ...
Aug 25, 2020 · This combination may increase the risk of respiratory depression and have a deleterious effect on sleep apnoea and oxygenation [2, 8]. However, ...
[96]
[Drugs affecting obstructive sleep apnea syndrome] - PubMed
Benzodiazepines, opioids, muscle relaxants, and male hormones adversely affect OSA. Also of clinical interest are drugs that do not affect OSA and can even ...
[97]
Polysomnographic Analysis of a Pediatric Case of Baclofen-Induced ...
Feb 15, 2019 · The muscle relaxant properties of baclofen can facilitate upper airway collapse during sleep and increase obstructive apneas.
[98]
Nasal obstruction as a risk factor for sleep-disordered breathing. The ...
Participants who reported nasal congestion due to allergy were 1.8 times more likely to have moderate to severe sleep-disordered breathing than were those ...
[99]
Association of allergic rhinitis with obstructive sleep apnea - NIH
Dec 21, 2018 · The prevalence of AR in OSA/SDB is considerably high and children with SDB suffering from a higher incidence of AR than non-SDB.
[100]
Alcohol as an independent risk factor for obstructive sleep apnea - NIH
Some studies [7] suggest that alcohol consumption increases the occurrence of hypoxia and apnea during sleep apnea episodes, but there are also some studies ...
[101]
Climate Change Increases Severity of Obstructive Sleep Apnea
May 18, 2025 · Rising temperatures increase the severity of obstructive sleep apnea (OSA), according to a large new study published at the ATS 2025 International Conference.
[102]
Patients with Obstructive Sleep Apnea at Altitude - PubMed
When OSA patients stay at altitudes above 1600 m, corresponding to that of many tourist destinations, hypobaric hypoxia promotes frequent central apneas in ...
[103]
Air Pollution and Respiratory Permeability in Obstructive Sleep Apnea
Nov 19, 2020 · PM may cause OSA through oxidative stress and inflammation. Air pollution increases permeability in the airway by reducing tight junction ...
[104]
Obstructive sleep apnea in shift workers - PubMed
The aim of the study was to investigate effects of shift work on obstructive sleep apnea syndrome (OSAS) and oxygen desaturation index (ODI) during daytime and ...
[105]
Dose-response relationship between weight loss and improvements ...
Even a < 5% weight loss can reduce respiratory events, but a ≥ 5% and ideally ≥ 10% weight loss is necessary for reducing the prevalence of severe OSA. Clinical ...ABSTRACT · METHODS · RESULTS · DISCUSSION
[106]
A Detailed Mechanistic Understanding of Positional and ...
Although it is known that OSA can occur in any position, a large percentage of patients. (50% to 60%) experience supine-predominant OSA. (sometimes referred to ...<|control11|><|separator|>
[107]
The undervalued potential of positional therapy in position ... - NIH
In the supine group, the treatment was successful (defined as an AHI < 10) in 61.4 % of the patients, none in the lateral group, and 84.6 % in the prone group.
[108]
Obstructive sleep apnea: Overview of management in adults
Sep 17, 2025 · OSA management after weight loss · - Nonsupine sleep position · - Alcohol, sedating, and select medications avoidance · POSITIVE AIRWAY PRESSURE ...Missing: sedatives | Show results with:sedatives
[109]
Sleep apnea - Symptoms and causes - Mayo Clinic
Apr 6, 2023 · The most common symptoms of obstructive and central sleep apneas include: Loud snoring. Episodes in which you stop breathing during sleep ...Diagnosis and treatment · Polysomnography (sleep study) · CPAP: How it works
[110]
Does Smoking Affect OSA? What about Smoking Cessation? - PMC
Aug 31, 2022 · Smoking cessation should improve OSA as upper airway oedema may reduce, but there is limited data to support this hypothesis. The impact of ...
[111]
Treating and Managing Sleep Apnea | American Lung Association
Jul 17, 2025 · Your healthcare provider often will recommend that you make some lifestyle changes along with other treatments. Maintain a healthy weight: ...
[112]
Obstructive Sleep Apnea (OSA) Treatment & Management
Jan 7, 2025 · General and behavioral measures, such as weight loss, avoidance of alcohol for 4-6 hours prior to bedtime, and sleeping on one's side rather ...
[113]
Treatment of Adult Obstructive Sleep Apnea With Positive Airway ...
The purpose of this systematic review is to provide supporting evidence for the clinical practice guideline for the treatment of obstructive sleep apnea ...
[114]
CPAP vs. APAP in the treatment of obstructive sleep apnea - PMC
APAP is as effective as CPAP in terms of normalization of the apnea-hypopnea index (AHI) and improvement in sleepiness, quality of life, and neurocognitive ...
[115]
Bilevel positive airway pressure for obstructive sleep apnea - PubMed
Bilevel positive airway pressure (BPAP) is potentially capable of treating OSA at a lower mean pressure than CPAP and can help augment ventilation via pressure ...
[116]
Effect of CPAP on Blood Pressure in Patients With Obstructive Sleep ...
Dec 11, 2013 · Among patients with OSA and resistant hypertension, CPAP treatment for 12 weeks, compared to control, resulted in a decrease in 24-hour mean and ...
[117]
Treatment of Sleep Apnea and Reduction in Blood Pressure
Mar 20, 2024 · Obstructive sleep apnea treatment reduces BP with substantial variability, not explained by the apnea-hypopnea index.
[118]
Treatments for obstructive sleep apnea: CPAP and beyond
Dec 1, 2023 · Poor CPAP adherence remains a concern, but adherence at 90 days and even at 1 year was reported as about 75% in recent studies, which is ...<|control11|><|separator|>
[119]
Clinical side effects of continuous positive airway pressure in ...
Mar 24, 2020 · A substantial number of OSA patients using CPAP suffer nasopharyngeal symptoms such as nasal dryness, rhinorrhoea and congestion, and dry mouth ...INTRODUCTION · INTERFACE-RELATED SIDE... · PRESSURE-RELATED SIDE...
[120]
Oral Appliances for Treatment of Snoring and Obstructive Sleep Apnea
MAD therapy is effective in improving sleep disordered breathing and quality of life in snoring and OSA patients.
[121]
The Tongue-Retaining Device: Efficacy and Side Effects in ... - NIH
The tongue-retaining device is a customized monobloc oral appliance used in the treatment of obstructive sleep apnea syndrome (OSAS).
[122]
Efficacy of Oral Appliance for Mild, Moderate, and Severe ... - PubMed
Feb 16, 2024 · Overall, both TRD and MAD are effective treatments for moderate and severe OSA. MAD is efficacious in mild OSA, while TRD requires further validation.
[123]
Efficacy and adherence of different mandibular advancement ...
Efficacy and adherence of different mandibular advancement devices designs in treatment of obstructive sleep apnea: A systematic review and meta-analysis.
[124]
Effectiveness of Mandibular Advancement Devices in Positional ...
Feb 20, 2024 · MADs are effective in reducing AHI in POSA and NPOSA patients from mild to very severe degree. Supine AHI decreased after treatment with MADs.
[125]
Clinical Practice Guideline for the Treatment of Obstructive Sleep ...
We recommend that sleep physicians consider prescription of oral appliances, rather than no treatment, for adult patients with obstructive sleep apnea who are ...
[126]
Management of side effects of oral appliance therapy for sleep ...
Some categories of side effects are not unique to oral appliance therapy: tissue-related side effects, appliance issues, and damage to teeth or dental work. The ...
[127]
Maxillomandibular Advancement for Treatment of Obstructive Sleep ...
The overall surgical success and cure rates for MMA as a treatment for OSA were 85.5% and 38.5%, respectively, for AHI data and 64.7% and 19.1%, respectively, ...
[128]
Long-term Efficacy of Uvulopalatopharyngoplasty among Adult ...
Jun 11, 2019 · Meta-analysis comparing long-term post- and preoperative outcomes showed significant improvements, with an 15.4 event/h (46.1%) decrease of ...
[129]
Long-term follow-up of patients operated with ...
Almost 50% of patients operated with UPPP were not satisfied with the result of the operation after about 20 years, and one third used CPAP at follow-up. A ...
[130]
Nyxoah receives FDA approval for Genio system
Aug 27, 2025 · On Aug. 8, 2025, Nyxoah announced that the FDA approved the Genio system for a subset of patients with moderate to severe obstructive sleep ...
[131]
Hypoglossal Nerve Stimulation Reduced Sleep Apnea Events
Oct 22, 2025 · Topline 12-month data showed a response rate of 65% with the device, and a 68% reduction in both AHI and oxygen desaturation events per hour.
[132]
Systematic Review and Meta-Analysis - PubMed
Jan 7, 2025 · Maxillomandibular advancement has the highest success rate for obstructive sleep apnea among current surgical treatments, with most sequelae being transient.
[133]
a systematic review and meta-analysis | Sleep and Breathing
Dec 9, 2024 · Among 427 patients, 377 (88.1%) were considered a surgical success. Previous meta-analyses performed also utilized such criteria yet lacked ...
[134]
Considerations in Surgical Management of Pediatric Obstructive ...
Tonsillectomy (with or without adenoidectomy) in pediatric OSA in otherwise healthy non-obese children has a success rate of approximately 75%. However, the ...
[135]
Treatment of Residual OSA in Children
Feb 9, 2023 · The success rate of adenotonsillectomy in obese children with OSA is less than that of nonobese children with OSA (24%-46% versus 80%).<|control11|><|separator|>
[136]
Complications of adenotonsillectomy for obstructive sleep apnea in ...
This study showed a low risk of post-adenotonsillectomy complications in school-aged healthy children with obstructive apnea although many children met ...Missing: cure | Show results with:cure
[137]
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Jun 21, 2024 · Tirzepatide reduced the AHI, body weight, hypoxic burden, hsCRP concentration, and systolic blood pressure and improved sleep-related patient-reported outcomes.
[138]
Overview of the Role of Pharmacological Management of ...
Potassium channel blockers have recently been identified as a potential pharmacological treatment for OSA. Monoamine withdrawal can reduce upper airway muscle ...
[139]
Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea ...
Solriamfetol significantly increased wakefulness and reduced sleepiness in participants with obstructive sleep apnea and excessive sleepiness.
[140]
[PDF] 211230Orig1s000 211230Orig2s000 - accessdata.fda.gov
Mar 20, 2019 · The review team agrees unanimously that the benefits of solriamfetol outweigh the risks in the treatment of EDS in patients with OSA and ...<|separator|>
[141]
Efficacy and Safety of Solriamfetol on Excessive Daytime Sleepiness ...
Oct 23, 2025 · Conclusions. Solriamfetol demonstrated substantial efficacy and acceptable safety in Chinese patients with OSA with EDS, reinforcing its role ...
[142]
FDA Approves First Medication for Obstructive Sleep Apnea
Dec 20, 2024 · The US Food and Drug Administration approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with ...
[143]
FDA approves Zepbound® (tirzepatide) as the first and only ...
Dec 20, 2024 · FDA approves Zepbound (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity.
[144]
Apnimed Reports Positive Topline Results from Second Phase 3 ...
LunAIRo was a 12-month study that evaluated the efficacy and safety of AD109 in adults with mild, moderate and severe OSA, across a wide range of weight ...
[145]
Aroxybutynin and atomoxetine (AD109) for the treatment of ...
Aroxybutynin and atomoxetine (AD109) for the treatment of obstructive sleep apnea: Rationale, design and baseline characteristics of the phase 3 clinical trials.
[146]
The Combination of Aroxybutynin and Atomoxetine in the Treatment ...
... AD109. The mechanism by which AD109 promotes improvement in OSA severity is likely enhanced upper airway muscle activity from noradrenergic stimulation by ...
[147]
Intranasal corticosteroid therapy for obstructive sleep apnoea ... - NIH
Conclusions: Intranasal fluticasone is of benefit to some patients with OSAS and rhinitis. The data suggest that this form of nasal obstruction may contribute ...
[148]
How do topical nasal corticosteroids improve sleep and daytime ...
Topical intranasal corticosteroids should be used to decrease nasal congestion and to improve sleep and daytime somnolence in patients manifesting these ...
[149]
Effects of intranasal steroids on continuous positive airway pressure ...
Oct 26, 2020 · The addition of an intranasal steroid decreased the frequency of nasal symptoms, especially rhinorrhea and congestion, among patients with OSA initiating CPAP ...
[150]
Effect of Theophylline on Sleep-Disordered Breathing in Heart Failure
Aug 22, 1996 · The present study shows that, as compared with placebo, theophylline resulted in a 51 percent reduction in the apnea–hypopnea index, mostly ...
[151]
Theophylline in obstructive sleep apnea. A double-blind evaluation
We conclude that theophylline may be beneficial in patients with OSA, but part of the improvement is due to a deterioration in sleep quality.
[152]
Pharmacotherapy for obstructive sleep apnea: a critical review of ...
Sep 12, 2025 · Our review critically examines the efficacy of pharmacologic treatments for OSA and highlights current limitations and future research ...
[153]
Pharmacological management of sleep apnea and obesity, a new ...
Aug 1, 2025 · Evaluating the potential of metabolic drugs in obstructive sleep apnea and obesity: a narrative review. J Clin Sleep Med. 2025;21(8):1433–1444.
[154]
Pharmacological interventions for the treatment of obstructive sleep ...
Feb 29, 2024 · Oxybutynin, Atomoxetine, and Reboxetine are three medications that have been found to have an impact on OSAS. The action mechanisms by which ...
[155]
Adherence to Continuous Positive Airway Pressure Therapy
When adherence is defined as greater than 4 hours of nightly use, 46 to 83% of patients with obstructive sleep apnea have been reported to be nonadherent to ...
[156]
Upper-Airway Stimulation for Obstructive Sleep Apnea
Jan 9, 2014 · We evaluated the clinical safety and effectiveness of upper-airway stimulation at 12 months for the treatment of moderate-to-severe obstructive sleep apnea.
[157]
Oral Appliance Treatment for Obstructive Sleep Apnea: An Update
Adverse effects primarily include excessive salivation, mouth dryness, tooth pain, gum irritation, headaches, and temporomandibular joint discomfort. Reported ...
[158]
Meta-analysis of all-cause and cardiovascular mortality in ... - PubMed
All-cause mortality (HR 0.66; 0.59-0.73) and cardiovascular mortality (HR 0.37; 0.16-0.54) were significantly lower in CPAP-treated than in untreated patients.Missing: reduction | Show results with:reduction
[159]
Impact of Patient Education on Compliance with Positive Airway ...
Apr 13, 2017 · Patient education with polysomnography chart view followed by frequent visits increased long-term compliance with PAP treatment.
[160]
Cardiovascular Disease Risk in Obstructive Sleep apnea: An Update
The Sleep Heart Health Study on 709 patients reported that OSA was independently associated with a 2.38 odds of having HF compared to controls [18]. Furthermore ...
[161]
Obstructive Sleep Apnea and Cardiovascular Disease: Role of the ...
Obstructive sleep apnea increases the risk of heart failure by 140%, the risk of stroke by 60%, and the risk of coronary heart disease by 30%. Thus, sleep apnea ...
[162]
Cardiovascular Mortality in Obstructive Sleep Apnea in the Elderly
Mar 11, 2012 · Compared with the control group, the fully adjusted hazard ratios for cardiovascular mortality were 2.25 (confidence interval [CI], 1.41 to 3.61) ...
[163]
The Epidemiology of Adult Obstructive Sleep Apnea - PMC
Factors that increase vulnerability for the disorder include age, male sex, obesity, family history, menopause, craniofacial abnormalities, and certain health ...
[164]
Economic burden of undiagnosed sleep apnea in U.S. is nearly $150B
Nov 8, 2017 · Frost & Sullivan calculated that the annual economic burden of undiagnosed sleep apnea among US adults is approximately $149.6 billion.
[165]
Sleep Apnea Economic Burden in U.S. Exceeds $150B Annually
Sep 2, 2025 · A 2023 Journal of Clinical Sleep Medicine study confirmed the staggering economic impacts, citing $15,482 in annual inpatient healthcare costs ...
[166]
Continuous Positive Airway Pressure Treatment of Mild to Moderate ...
Nov 6, 2006 · Conclusions: OSA treatment was associated with a cardiovascular risk reduction of 64% independent from age and preexisting cardiovascular ...
[167]
Positive Airway Pressure, Mortality, and CV Risk in Older Adults With ...
Sep 11, 2024 · Obstructive sleep apnea (OSA) is highly prevalent (9%-37% in men and 4%-50% in women), affecting nearly 1 billion people worldwide. OSA becomes ...
[168]
Global warming may increase the burden of obstructive sleep apnea
Jun 16, 2025 · High ambient temperatures are associated with reduced sleep duration and quality, but effects on obstructive sleep apnea (OSA) severity are unknown.
[169]
Screening for Obstructive Sleep Apnea in Adults: US Preventive ...
Nov 15, 2022 · The current prevalence of obstructive sleep apnea (OSA) in the US is not well established. Based on cohort and survey data from 2007-2010 ...
[170]
The Global Burden of Obstructive Sleep Apnea - PMC
Apr 25, 2025 · Low socioeconomic status is a risk factor for cardiovascular disease among adult obstructive sleep apnea syndrome patients requiring treatment.
[171]
Unmasking obstructive sleep apnea: Estimated prevalence and ...
A strong relationship between age and gender was observed, with OSA prevalence 4-fold higher in older adults, aged 65 years, than younger adults less than 40 ...
[172]
Pediatric Obstructive Sleep Apnea: Diagnostic Challenges and ...
Dec 8, 2024 · They found that 25% of children with OSA did not have ... Effect of sleep disorders on blood pressure and hypertension in children.
[173]
Prevalence of Sleep-disordered Breathing in Women - ATS Journals
Nov 15, 1999 · Most estimates of the male/female ratio in the general public range between 2:1 and 4:1. It has been suggested that sleep apnea is uncommon in ...
[174]
Sex differences in sleep and sleep-disordered breathing
The prevalence of OSA is about twice as high in men as in women up to the age of 50, but after the menopause, it is almost as high in women as in men.<|control11|><|separator|>
[175]
Evaluation of Obstructive Sleep Apnea in Female Patients in Primary ...
Female patients with obstructive sleep apnea are more likely underdiagnosed and present atypical symptoms, such as insomnia and depressive symptoms, leading to ...
[176]
SLEEP APNOEA IN THE ELDERLY: A GREAT CHALLENGE FOR ...
OSA is associated with pathological processes that may accelerate aging and aging related processes; aging may cause physical and neurological changes.
[177]
REM obstructive sleep apnea: prevalence and clinical associations ...
The prevalence of moderate to severe sleep-disordered breathing is estimated to be about 10% in males aged 30–49 years, 17% in males aged 50–70 years, 3% in ...
[178]
Disparities in the Diagnosis and Treatment of Obstructive Sleep ...
Johnson and colleagues reported only 5% of the 24% of African American participants with moderate/severe OSA received a physician's diagnosis (9). Other factors ...
[179]
Socioeconomic disparities in obstructive sleep apnea - ResearchGate
Jan 16, 2021 · A systematic review confirmed that individuals with lower income levels are at consistently higher risk of OSA across diverse populations [32], ...
[180]
The Effect of Patient Neighborhood Income Level on the Purchase of ...
May 22, 2015 · Patients who accepted CPAP were more likely to live in a higher-income neighborhood. Cumulative incidence of CPAP acceptance at 6 months was 43% ...
[181]
Projecting the 30-year burden of obstructive sleep apnoea in the USA
Aug 26, 2025 · Interpretation: Projections indicate that obstructive sleep apnoea will affect 76·6 million adults aged 30-69 years across the USA in 2050, ...
[182]
Estimation of the global prevalence and burden of obstructive sleep ...
This is the first study to report global prevalence of obstructive sleep apnoea; with almost 1 billion people affected, and with prevalence exceeding 50% in ...
[183]
National indicator report details importance of OSA diagnosis ...
Apr 4, 2023 · Obstructive sleep apnea affects nearly 30 million Americans, and an estimated 80% of cases remain undiagnosed. Untreated sleep apnea can ...
[184]
New campaign to raise awareness that sleep apnea is 'more than a ...
Feb 9, 2023 · This campaign will inform the public that untreated sleep apnea is “More than a Snore,” affecting a person's long-term health and quality of life.
[185]
AASM launches 'Sleep is Good Medicine' campaign to help ...
Jun 5, 2022 · Today, the AASM launched “Sleep is Good Medicine,” a national campaign to increase public education about the importance of sleep.
[186]
Celebrating World Sleep Day 2024 - AASM Foundation
Mar 14, 2024 · The AASM Foundation is joining the World Sleep Society to celebrate Word Sleep Day with an interactive activity for children and their parents and/or ...
[187]
Snoring Is Not Funny - Donald R. Tanenbaum, DDS MPH
For years snoring has prompted humorous cartoon depictions of bed partners sorting out their different views of the problem and hilarious videos revealing what ...Missing: stigma | Show results with:stigma
[188]
The sound of silence: women keep quiet about snoring, sleep apnea
Aug 10, 2022 · Many women keep quiet about snoring and sleep apnea, but stigmas can keep women from seeking help for their problems.
[189]
Gender Bias & OSA Diagnosis in Women - Resmed Sleep Institute
Jul 14, 2025 · A growing body of research shows how gender biases and stereotypes of obstructive sleep apnea stand in the way of women receiving the help ...
[190]
These Celebrities Have Sleep Apnea – Did You Know?
In this article, we'll share celebrities who have dealt with sleep apnea, while also focusing on the importance of treatment and other common questions about ...Missing: post- | Show results with:post-
[191]
Obstructive sleep apnea associated with increased risks for Long ...
May 11, 2023 · Among people who have had COVID-19, adults with obstructive sleep apnea were more likely to experience long-term symptoms suggestive of long ...Missing: google | Show results with:google
[192]
Climate change linked to dangerous sleep apnea - EurekAlert!
Jun 16, 2025 · A new study, published in leading journal, Nature Communications, found that rising temperatures increase the severity of obstructive sleep apnea (OSA).
[193]
https://www.resmedsleepinstitute.com/clinical-guidelines/gender-bias-and-osa-diagnosis-in-women
[194]
https://www.sleepadvisor.org/celebrities-with-sleep-apnea/
[195]
The European Insomnia Guideline: An update on the diagnosis and ...
Nov 28, 2023 · If the screening questionnaire is positive for OSA, a home sleep apnea test or PSG is required for a valid diagnosis of OSA. Insomnia is a ...
[196]
Sleep Apnea Test at Home with Insurance: Tutorial | BlueSleep
Home sleep tests are covered by insurance only when prescribed by a health care provider and only when necessary due to a high suspicion of sleep apnea. A ...
[197]
[PDF] Obstructive Sleep Apnea and Cardiovascular Disease in Africa
The limited data available consistently show that many African adults carry risk factors for OSA (middle age, obesity) and often exhibit OSA- related symptoms.
[198]
Resilience in Health Care: The Role of Telemedicine and e-Health ...
In the acute COVID-19 (AcuteCOV) period, telemedicine visits comprised 47% of all visits. In the post-acute COVID-19 (PostAcuteCOV) period, telemedicine ...
[199]
Telemedicine home CPAP titration and follow-up in the COVID-19 ...
This study aimed to compare successful CPAP adaptation and compliance with home telemedicine CPAP titration with the usual method based on face-to-face visits.
[200]
Continuous Positive Airway Pressure (CPAP) therapy - Medicare
Medicare may cover a 12-week trial of CPAP therapy (including devices and accessories) if you've been diagnosed with obstructive sleep apnea.
[201]
Implementation of European national driving regulations for ...
All EU members had introduced the Directive into national regulations, largely unchanged, although some countries applied stricter criteria such as mild OSA and ...
[202]
Validation of the European Obstructive Sleep Apnea Screening ...
Oct 8, 2024 · The EUROSAS provides a moderate level of accuracy for the screening of OSA in the professional male drivers.
[203]
Identifying Barriers to Obstructive Sleep-Disordered Breathing Care
Seid et al developed a model of 'barriers to care' based on parent responses to themes pertaining to healthcare access for children, providing a standardized ...
[204]
Health disparities in the detection and prevalence of pediatric ...
Aug 9, 2023 · If PSG completion and OSA detection are delayed or not completed because of such barriers, children may be older at the time of diagnosis ...
[205]
https://publications.ersnet.org/content/erj/66/1/2402484
[206]
Inspire Upper Airway Stimulation – P130008/S090 - FDA
Jul 13, 2023 · The approval also increases the upper limit for recommended body mass index (BMI) to 40 (increase from ≤32 to ≤40). How does it work? The IPG ...Missing: expansion broader
[207]
Inspire Medical Systems, Inc. Announces FDA Approval for Apnea ...
Jun 9, 2023 · “We are excited that the FDA has approved Inspire's application to expand our indication to include patients with AHI up to 100 events per hour, ...
[208]
Response to Hypoglossal Nerve Stimulation Changes With Body ...
Apr 4, 2024 · This study provides evidence supporting the use of HGNS as a treatment for obstructive sleep apnea, but sleep medicine clinicians should be aware that higher ...
[209]
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Jun 21, 2024 · Among persons with moderate-to-severe obstructive sleep apnea and obesity, tirzepatide reduced the AHI, body weight, hypoxic burden, hsCRP ...Missing: approval | Show results with:approval
[210]
https://www.fda.gov/medical-devices/recently-approved-devices/inspire-upper-airway-stimulation-p130008s090
[211]
Aroxybutynin and atomoxetine (AD109) for the treatment of ...
Aug 17, 2025 · Aroxybutynin and atomoxetine (AD109) for the treatment of obstructive sleep apnea: Rationale, design and baseline characteristics of the phase 3 ...
[212]
Machine Listening for OSA Diagnosis: A Bayesian Meta-Analysis
Results: Machine listening exhibited high diagnostic accuracy with a sensitivity of 90.3%, specificity of 86.7%, and a diagnostic OR of 60.8, with better ...
[213]
The Correlation of Computerized Scoring in Home Sleep Apnea ...
Jul 18, 2024 · When combining the moderate and severe OSA groups into a single category, the sensitivity was 90%, specificity was 100%, PPV was 100%, and NPV ...<|control11|><|separator|>
[214]
Enhancing artificial intelligence‐driven sleep apnea diagnosis: The ...
Dec 15, 2024 · This review aims to highlight the pivotal role of the mandibular jaw movement (MJM) signal in advancing artificial intelligence (AI)-powered technologies for ...
[215]
Climate Change Intensifies Sleep Apnea Risk: ATS 2025 - EMJ
May 19, 2025 · A new study presented at ATS 2025 reveals that rising temperatures significantly worsen obstructive sleep apnea severity, with the global ...
[216]
Apnimed To Present Additional Phase 3 Data for AD109, an ...
Oct 17, 2025 · Apnimed To Present Additional Phase 3 Data for AD109, an Investigational Oral Pill for Obstructive Sleep Apnea, at CHEST 2025 Annual Meeting.
[217]
Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA
Oct 14, 2025 · We also aimed to investigate weight-dependent and weight-independent effects of tirzepatide treatment for OSA using linear regression analysis.Missing: extension trial
[218]
Designer Receptors Exclusively Activated by Designer Drugs ...
Feb 14, 2020 · The goal of the current study was to develop a novel and minimally invasive gene therapy approach for treating OSA. We used mice with diet- ...Missing: directions | Show results with:directions
[219]
Adenotonsillectomy vs Watchful Waiting in Pediatric Mild to ...
Sep 18, 2025 · This randomized clinical trial compares adenotonsillectomy vs watchful waiting for treating children aged between 2 to 4 years with mild to ...
[220]
Testing a Consumer Wearables Program to Promote the Use ... - NIH
Sep 19, 2024 · Adherence to treatment can improve sleep quality, reduce the risk of OSA-related comorbidities, and improve quality of life [6]. However, low ...
[221]
https://pubmed.ncbi.nlm.nih.gov/41135142/